Top

Naifa Lamki Busaidy, M.D., F.A.C.P., F.A.C.E.

Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine

About Dr. Naifa Lamki Busaidy

My clinical expertise and research interests are focused on endocrine and metabolic effects of cancer therapy. I have served as PI or collaborator on various trials evaluating metabolism in cancer patients. These investigations have included effects of metabolism on the cancer and its therapies and response rates.

Having served on various panels and done research in that arena, coupled with well-established collaborators in a research environment that contains other funded investigators who are doing complementary research helps to assure that these research goals are accomplished.

Primary Appointment

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Education & Training

Degree-Granting Education

2007	Clinical Research Curriculum Certificate ,The University of Texas Medical School, Houston, Texas, US, MD
1997	Baylor College of Medicine, Houston, Texas, US, MD
1993	Houston Baptist University, Houston, Texas, US, Biology and Psychology, BS

Postgraduate Training

2003-2004	Research Fellowship, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, Houston, Texas
2001-2003	Clinical Fellowship, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, Houston, Texas
1998-2001	Clinical Residency Internal Medicine, Baylor College of Medicine, Houston, Texas
1997-1998	Clinical Transitional Internship, The Royal Hospital and The Sultan Qaboos University Hospital, Sultanate of Oman

Licenses & Certifications

2024	American Board of Internal Medicine, Endocrinology, Diabetes and Metabolism
2022	Georgia Composite Medical Board
2022	Mississippi State Board of Medical Licensure
2022	Washington State Department of Health
2022	Tennessee Board of Medical Examiners
2022	Oklahoma State Board of Medical Licensure
2022	Louisiana State Board of Medical Examiners
2022	Arizona Board of Medical Examiners
2022	Alabama Board of Medical Examiners
2021	Florida Board of Medicine
2003	American Board of Internal Medicine, Endocrinology, Diabetes and Metabolism
2001	American Board of Internal Medicine, Internal Medicine
null	Texas Medical Board

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2020

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2012

Administrative Appointments/Responsibilities

Director, Thyroid Nodule Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - Present

Other Professional Positions

Thyroid Cancer Expert, Eisai, The Woodlands, Texas, 2024 - Present

Thyroid Cancer Advisory Board, Eisai, Washington, DC, 2023 - Present

Chair, Women-in-Thyroidology, American Thyroid Association, Houston, TX, 2023 - 2024

Thyroid Cancer Virtual Advisory Board, Exelixis, Houston, TX, 2023 - Present

Chair-elect, Women-in-Thyroidology, American Thyroid Association, Houston, TX, 2022 - 2023

Chair, ITOG Membership Committee, International Thyroid Oncology Group (ITOG), Houston, TX, 2022 - 2024

Board Liaison, American Thyroid Association, Houston, TX, 2022

Thyroid Cancer Virtual Advisory Board, Exelixis, Houston, TX, 2021

Thyroid Cancer Virtual Advisory Board, Exelixis, Houston, TX, 2021 - Present

Committee Member, Thyroid International Recommendations Online (TIRO), Houston, TX, 2021 - Present

Member, Board Member, Thyroid International Recommendations Online (TIRO), Houston, TX, 2021 - Present

Member, Steering & Planning Committee, World Congress on Thyroid Cancer, Boston, MA, 2021

Member, ATA Diversity, Equity and Inclusion Task Force, American Thyroid Association, Houston, TX, 2019 - Present

Board Member, American Thyroid Association, Houston, TX, 2019 - 2023

Consultant, Strategic Planning Retreat, American Thyroid Association, Phoenix, AZ, 2019

Planning Committee, MEN 2019, 16th International Workshop on Multiple Endocrine Neoplasia, Houston, TX, 2019

Steering & Planning Committee, World Congress on Thyroid Cancer, Rome, 2019

Consultant, Medullary Thyroid Cancer, Loxo Oncology, United States, 2018

Member, Awards Committee, American Thyroid Association, Houston, TX, 2018 - 2021

Member, Thyroid Scientific Committee (at the request of the AACE President), American Association of Clinical Endocrinologists (AACE), Jacksonville, FL, 2017 - Present

Panel Member, American Head and Neck Society, Endocrine Section, United States, 2017 - Present

Co-Chair, Endocrine Tumor Multidisciplinary Research Series, Endocrine and Head and Neck Surgery, Houston, TX, 2016 - 2019

Member, Rare Tumor Working Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present

Co-Chair, Journal Club, Endocrinology Fellowship Conference, Houston, TX, 2015 - Present

Committee Member, Academic Endocrinologists, American Association of Clinical Endocrinologists, Jacksonville, FL, 2015

Panel Member, National Cancer Comprehensive Network, Ft. Washington, PA, 2015 - Present

Member, Task Force on Fellows Research Grant, American Association of Clinical Endocrinology, United States, 2015 - 2018

Member, Thyroid Cancer Survivors' Association (ThyCa) Medical Advisory Council (MAC), Onley, MD, 2014 - Present

Co-Chair, Advisory Board, Bayer, United States, 2014 - 2016

Consultant, Eisai, United States, 2014 - 2018

Member, Research Committee, American Thyroid Association, Falls Church, VA, 2013 - 2017

Consultant, Metabolism and Endocrine Expert, Clovis, United States, 2013

Member, Website Committee, International Thyroid Oncology Group, Yorkville, NY, 2013 - Present

Member, Southwest Oncology Group Early Therapeutics Committee, Houston, TX, 2013 - Present

Co-Facilitator, Morbidity and Mortality Conference, Department of Endocrine, Houston, TX, 2013 - Present

Member, International Thyroid Oncology Group, Anaplastic Thyroid Cancer Committee, Yorkville, NY, 2012 - 2016

Member, Southwest Oncology Group (SWOG), Houston, TX, 2012 - Present

Member, The American Thyroid Association Annual Meeting Program Committee, Falls Church, VA, 2011 - 2014

Mentor, Endocrine Society's Mentor Exchange Program, Chevy Chase, MD, 2010 - 2017

Facilitator, Clinical and Basic Research Conference, Department of Endocrine Neoplasia and Hormonal Disorders, Houston, TX, 2008 - Present

Endocrine Consultant, National Cancer Institute, Bethesda, Maryland, 2008 - 2009

Endocrine Consultant, National Cancer Institute, Bethesda, Maryland, 2008 - 2014

Faculty Advisor, Diabetes, Endocrinology and Metabolism Program, Baylor College of Medicine, Houston, TX, 2008 - Present

Member, Endocrine Consultant, The University of Texas System ICU Collaborative Group, Houston, TX, 2006 - 2009

Member, Baylor College of Medicine, Endocrinology Fellowship Curriculum Committee, Houston, TX, 2004 - Present

Extramural Institutional Committee Activities

Member, Search Committee - Head and Neck Surgeon, The University of Texas MD Anderson Cancer Center, 2021 - 2023

Member, Division of Internal Medicine Clinic Toxicity Working Group, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Division of Internal Medicine Research Toxicity Working Group, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, 49 States Workstream - Rare Tumor, The University of Texas MD Anderson Cancer Center, 2020 - 2023

Member, Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2023

Member, Chemotherapy Induced Nausea and Vomiting Working Group, The University of Texas MD Anderson Cancer Center, 2019

Member, Division of Internal Medicine Research Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2019

Member, Endocrine Center Website Committee, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2017 - 2019

Member, Clinical Safety and Effectiveness, The University of Texas MD Anderson Cancer Center, 2017 - 2019

Member, Clinical Operations Committee (CLOPS), Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 2016 - 2020

Departmental Representative, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2016 - 2017

Member, Facilitating Anaplastic Thyroid Cancer for Specialized Treatment (FAST) Task Force, The University of Texas MD Anderson Cancer Center, 2016 - Present

Chair, Thyroid Nodule Molecular Markers Taskforce, The University of Texas MD Anderson Cancer Center, 2016 - 2019

Member, Clinical Research Operations Committee, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 2015 - Present

Chair, Endocrine Tumor Targeted Therapy Management Taskforce, The University of Texas MD Anderson Cancer Center, 2015 - Present

Member, Language of Caring Steering Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2016

Member, Oncologic Endocrine Fellowship Program Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, Inclusiveness Committee, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2013 - 2015

Chair, Search Committee for Assistant Professor, Tenure Track, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Member, Gender Inclusiveness Committee, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2013 - 2023

Member, Medullary Thyroid Cancer Multidisciplinary Working Group, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Member, Pregnancy Testing Policy Working Group, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Credentials Committee of the Medical Staff (CCMS), The University of Texas MD Anderson Cancer Center, 2010 - 2012

Member, Metrics Task Force, CE Subcommittee, The University of Texas MD Anderson Cancer Center, 2010 - 2013

Member, Clinical Effectiveness Focus Group, The University of Texas MD Anderson Cancer Center, 2010

Departmental Liaison, Women Faculty Programs Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2015

Member, Heart of Leadership Core Skills Program, The University of Texas MD Anderson Cancer Center, 2009

Department Representative, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2009 - 2010

Member, Junior Faculty Mentoring Task Force, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2009

Department Representative, Clinical Effectiveness Subcommittee, Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2008 - 2011

Member, Junior Faculty Development Focus Group, The University of Texas MD Anderson Cancer Center, 2007

Member, Diabetes Working Group, The University of Texas MD Anderson Cancer Center, 2007 - 2009

Mentor, Junior Faculty Development Panel, The University of Texas MD Anderson Cancer Center, 2007

Member, Clinical Effectiveness Steering Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2009

Member, Division of Internal Medicine Research Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2010

Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2009

Member, Search Committee for Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 2005

Endocrine Consultant, ICU Committee for Glycemic Control, The University of Texas MD Anderson Cancer Center, 2004 - 2007

Member, Insulin Drip Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2008

Member, Diabetes Advisory Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2008

Member, Internal Advisory Committee, Integrative Medicine, The University of Texas MD Anderson Cancer Center, 2003 - 2007

Member, Diversity Council, The University of Texas MD Anderson Cancer Center, 2002 - 2003

Fellow Representative, Endocrinology Fellowship Curriculum Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2004

Member, Search Committee - Pathology, The University of Texas MD Anderson Cancer Center

Member, Biomarker Oversight Committee, The University of Texas MD Anderson Cancer Center

Member, Search Committee - Head and Neck Surgeon, The University of Texas MD Anderson Cancer Center

Editorial Activities

Editor, BioMed Research International, 2017 - Present

Reviewer, Dataset Papers in Medicine, 2012

Honors & Awards

2020	Top Endocrinologist 2020, Top Doctors
2019 - 2023	Board of Directors, American Thyroid Association
2018 - 2024	Board of Directors, The International Thyroid Oncology Group
2012 - 2024	Fellow, American College of Endocrinology
2012 - 2024	Invited Member, The International Thyroid Oncology Group
2011	Marquis Who's Who in Medicine and Healthcare
2011	America's Top Physicians
2010	Fellow, American College of Physicians
2010	Research Highlight in Nature Reviews Endocrinology
2009	Finalist-Cyrus Scholar Award Clinical Research-Division of Medicine Research Retreat, April
2008 - 2009	University of Texas MD Anderson Cancer Center Apple Award Recipient
2007	International Award for Excellence in Published Clinical Research in The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society & Pfizer, Inc
2007	Cambridge, Who's Who
2007	One of the 100 Contributions to Making Cancer History
2006	Apple Award Health Education Week-patients
2006	1st Place, National Patient Safety Week Award,, Selected and Awarded by Kenneth Shine, M.D., Vice Chancellor of the University of Texas Health System
2006	1st Prize Clinical Research Award, Division of Internal Medicine Retreat
2006	Best Collaborator Award, Division of Internal Medicine Retreat
2004	Selected for Endocrine Society Clinical Investigators Trainee Workshop
2004	Second Prize Clinical Research, Project- Annual Trainee Research Award, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center
2004	Selected for Endocrine Fellows Foundation Diabetes Preceptorship, Joslin Diabetes Center, Harvard University
2003	3rd Prize Clinical Research Award, Baylor College of Medicine Research Symposium
1994	Baylor Students’ Association
1994	Selected for Baylor Medical School Admissions Committee Member
1993	Miss Houston Baptist University
1993	Cum Laude, Bachelor of Science in Biology and Psychology, Houston Baptist University
1993	Houston Baptist University Woman of the Year
1992	Selected into Alpha Epsilon Delta Elected Member
1991	Omicron Delta Kappa
1991	Chosen as Student Foundation Member
1991	DeBakey Summer Surgery Program
1991	National Dean’s List, U.S.A
1991	Who's Who Among Students in American Universities and Colleges
1990	Alpha Chi Honor Society
1990	Academic Scholarships
1990	Dean's List

Professional Memberships

American Society of Clinical Oncology

2015 - Present

National Comprehensive Cancer Network

2015 - Present

ThyCa Medical Advisory Council (MAC)

2014 - Present

Cancer Center Support Grant Head and Neck Cancer Program

2014 - Present

The International Thyroid Oncology Group

2012 - Present

American Thyroid Association

2009 - Present

Member, American Journal of Medical Quality

2006 - 2007

American Diabetes Association

2005 - 2015

Harris County Medical Society

2005 - Present

Arab American Medical Association-Houston Chapter

2004 - 2005

Arab American Medical Association-Houston Chapter

2004 - Present

Endocrine Society

2003 - Present

American Association of Clinical Endocrinologists

2002 - Present

National Arab American Medical Association

2001 - Present

American College of Physicians

1999 - Present

Texas Medical Association

1995 - 2004

American Medical Association

1995 - 2006

Selected Presentations & Talks

Local Presentations

2024. Adverse Events: Monitoring and Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
2024. Thyroid Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2024. Thyroid Cancer: I131 Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. Thyroid Cancer: I131 Therapy. Conference. The University of Texas MD Anderson Cancer Center Department of Head and Neck Surgery Section of Oral Oncology & Maxillofacial Prosthodontics. Houston, TX, US.
2022. Adverse Events: Monitoring and Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. Revolutionizing the Treatment of Anaplastic Thyroid Carcinoma. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. Thyroid Cancer: I 131 Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Thyroid Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Adverse Events: Monitoring and Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Atezolizumab Combinations with Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Atezolizumab combinations in Anaplastic Thyroid Carcinoma. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Thyroid Cancer: I131 Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2020. Adverse Events: Monitoring and Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2020. Inclusion Has Many Faces. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Adverse Events: Monitoring and Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Systemic Therapy for Thyroid Cancer. Conference. Baylor College of Medicine. Houston, TX, US.
2019. Thyroid Cancer: I131 Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Radioiodine: Adjuvant and Therapeutic Functional Imaging. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Adverse Events: Monitoring and Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Thyroid Cancer and Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Radioiodine: Adjuvant and Therapeutic Functional Imaging. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Under One Sky; Promoting Religious Diversity. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. Evaluation of Recurrent Thyroid Disease. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2016. MTC Tumor Board - Clinical Case Discussion. Conference. The University of Houston MD Anderson Cancer Center. Houston, TX, US.
2015. Diagnosis and Management of Thyroid Nodules. Conference. University of Texas, MD Anderson Cancer Center. Houston, TX, US.
2012. Medullary Thyroid Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Thyroid Cancer: I131Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Advances in the Systemic Therapy of Medullary Thyroid Carcinoma. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Medullary Thyroid Cancer. Conference. Parathyroid Surgical Grand Rounds. Houston, TX, US.
2011. Metabolic Consequences of Targeted Therapies for Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. Diabetes Treatment: What is the Evidence. Conference. Houston Diabetes Patient Conference. Houston, TX, US.
2010. Metabolic Consequences of Targeted Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. Differentiated Thyroid Carcinoma- beyond surgery. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Endocrine Tumors, Medical Oncology Fellows Conference. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Diabetes in the Cancer Patient, Investigational Cancer Therapeutics Grand Rounds. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Tight Glycemic Control in Hospitalized Patients, Institutional Grand Rounds. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Abnormal Thyroid Function Test: Are They Real Abnormal?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Perioperative Glycemic Control – Much Ado About Nothing?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Clinical Trials, Evidenced-Based Medicine Workshop. Conference. The University of Texas Health Science Center Medical School. Houston, TX, US.
2006. Diabetes Mellitus and Patients Undergoing Curative Resection for Pancreatic Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Our Family Surviving Cancer: The Impact of Our Culture In Cultural Diversity in Cancer Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Diabetes Management and the Cancer Patient. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2012. Differentiated Thyroid Carcinoma. Conference. Head and Neck Surgery Conference, US.
2010. Thyroid Carcinoma-The Oral Manifestations, Dental Oncology Conference. Conference. The University of Texas MD Anderson Cancer Center, US.
2009. Thyroid Nodules: Where Are We?. Conference. Texas Nurse Practitioner Conference. Woodlands, TX, US.
2008. Diabetes: An Update. Conference. Arab American Medical Association, US.
2007. Thyroid Dysfunction - An Update Prime Care. Conference. Primary Care for Physicians. Beaumont, TX, US.

National Presentations

2025. TKI-Directed Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Invited. Targeted Oncology Community Case Forum. Houston, Texas, US.
2025. I’ve had surgery followed by radioactive iodine. Now I have non-avid (RAI resistant) disease. Do I start systemic therapy or we watch my disease?. Invited. 28th International Thyroid Cancer Survivors Conference. Houston, Texas, US.
2025. Educating the Next Generation of Thyroidologists. Panelist. American Thyroid Association. Scottsdale, Arizona, US.
2025. Update on Oncocytic Carcinoma. Panelist. American Thyroid Association. Scottsdale, Arizona, US.
2025. Anaplastic Thyroid Cancer. Invited. American Thyroid Association. Scottsdale, Arizona, US.
2025. Parathyroid Carcinoma Cases. Invited. Multidisciplinary Parathyroid Conference. Dallas, Texas, US.
2024. Retiring the Words Burnout and Resiliency (Planned by Women in Thyroidology). Invited. American Thyroid Association. Chicago, Illinois, US.
2024. Being your own patient advocate. Do I have the right medical team for my situation? Should I consider getting a second opinion? Do I need an oncologist for my care?. Invited. 27th International Thyroid Cancer Survivors' Conference. Houston, Texas, US.
2024. Long term management of medullary thyroid cancer after surgery – how should I be followed and for how long?. Invited. 27th International Thyroid Cancer Survivors' Conference. Houston, Texas, US.
2024. The Endocrinologist's Perspective on Surgical Management of Thyroid Cancer. Invited. AHNS-ES Webinar, US.
2024. Managing Advanced Thyroid Cancer. Invited. American Association of Endocrine Surgeons. Dallas, TX, US.
2023. Molecular mechanisms of resistance of thyroid cancer redifferentiation therapies. Conference. American Thyroid Association. Washington DC, US.
2022. Utilization of Molecular Markers in Management of Advanced Thyroid Cancer. Invited. 2022 UPMC Multidisciplinary Thyroid Cancer Symposium. Virtual - Houston, TX, US.
2022. Preparation for Radioactive Iodine Therapy in Thyroid Cancer. Invited. 1st Annual Arab Thyroid Association Conference. Houston - Virtual, TX, US.
2022. Update on MTC. Invited. 1st Annual Arab Thyroid Association Conference. Houston - Virtual, TX, US.
2022. Medullary Thyroid Cancer: Advances in Treatment and Follow-up. Invited. Chilean Society of Endocrinology and Diabetes. Houston - Virtual, TX, US.
2022. Evaluation and Management of Aggressive Thyroid Cancer. Invited. Middle East and North Africa First Thyroid Cancer Symposium. Houston - Virtual, TX, US.
2022. Fundamentals of Thyroid Cancer. Invited. AACE Communities China. Houston - Virtual, TX, US.
2022. Management of Medullary Thyroid Cancer. Conference. HMP Education-Rare Cancers Updates. Houston - Virtual, TX, US.
2022. Metastatic thyroid cancer. Invited. AACE Endocrine University. Houston - Virtual, US.
2021. Medullary thyroid cancer: Medical management at the beginning of the journey. Invited. Thyroid Cancer Survivors' Association. Houston, TX, US.
2021. Friday Clinical Oral Abstracts Session-Chair. Conference. American Thyroid Association. Houston - Virtual, TX, US.
2021. Systemic therapy for radioiodine-refractory Medulary Thyroid Cancer: an update. Invited. EndoPeru2021. Houston - Virtual, TX, US.
2021. Update on Systemic Therapy - Advances in the Management of Thyroid Cancer. Invited. AACE 2021. Houston - Virtual, TX, US.
2021. Thyroid Dysfunction - Primary and Central. Conference. ENDO 2021. Houston - Virtual, TX, US.
2021. Metastatic thyroid cancer. Invited. AACE Endocrine University. Houston - Virtual, TX, US.
2020. Bullseye! Targeted Therapies for Advanced Thyroid Cancer. Invited. The USC Peter A. Singer Thyroid Symposium 2020. Houston - Virtual, TX, US.
2020. Biomarker testing: Advanced cancer that needs testing to look for NTRK, RET and other therapeutic targets. Conference. ThyCA. Houston - Virtual, TX, US.
2020. Updates in Diagnosis in Management of Checkpoint Inhibitor related Endocrinopathies. Invited. MA-AACE Annual Meeting. Houston - Virtual, TX, US.
2020. THYCA Medullary thyroid cancer: Medical management at the beginning of the journey. Conference. ThyCa. Houston - Virtual, TX, US.
2020. Clinical Application of Molecular Testing in the Treatment of Advanced and Metastatic Thyroid Carcinoma: Differentiated Thyroid Carcinoma, Controversies in Thyroidology. Invited. ATA Spring Symposium, Virtual Meeting. Virtual Meeting, US.
2020. ATA Controversies in Thyroidology: How Molecular Testing Guides Therapy for Differentiated Thyroid Carcinoma. Invited. ATA Spring Meeting. New York (Online due to COVID-19), NY, US.
2019. Emergence of Resistance-Associated Mutations of RET V804M and KRAS in Medullary Thyroid Carcinoma (MTC) Patients Treated with Tyrosine Kinase Inhibitors (TKI) Cabozantinib and Vandetanib. Conference. 89th Annual Meeting of the American Thyroid Association. Chicago, IL, US.
2019. Advanced Differentiated Thyroid Cancer. Invited. Thyroid Cancer Survivor's Conference (THYCA). Denver, CO, US.
2019. Novel Use of a CLIA-certified CDKN2C Loss Assay in Sporadic Medullary Thyroid Carcinoma. Conference. North American Neuroendocrine Tumor Society. Boston, MA, US.
2019. Opening Plenary Session - Clinical Review: Recent Developments and Future Challenges in Thyroidology. Invited. American Thyroid Association - 89th Annual Meeting. Chicago, IL, US.
2019. Redifferentiation radioiodine (RAI)-therapy in patients (pts) with metastatic papillary, follicular and poorly differentiated thyroid cancer (TC). Conference. 89th Annual Meeting of the American Thyroid Association. Chicago, IL, US.
2019. Systemic Therapy in Medullary Thyroid Cancer, Meet the Professor. Invited. American Thyroid Association - 89th Annual Meeting. Chicago, IL, US.
2019. Endocrine Oncology. Invited. AACE Intensive Review of Endocrinology and Metabolism. Cleveland, OH, US.
2019. Endocrine Tumor Board: Management of Advanced Thyroid Malignancy - The Evolving Role of Targeted Therapy and Surgery. Invited. American Head and Neck Society (AHNS). Austin, TX, US.
2019. Combination vemurafenib (BRAF inhibitor)/cobimetinib (MEK inhibitor)/atezolizumab (anti-PDL1i) in BRAF-V600E mutated thyroid cancer (ATC): initial safety and feasibility. Conference. Endocrine Society, ENDO 2019. New Orleans, LA, US.
2019. Metastatic DTC: Local and Systemic Therapy. Invited. Advances in Medical and Surgical Management of Thyroid Cancer. Tampa, FL, US.
2019. Radioactive Iodine Therapy. Invited. Advances in Medical and Surgical Management of Thyroid Cancer. Tampa, FL, US.
2018. MTC Preoperative Recognition and Work-up. Invited. Surgery of Thyroid and Parathyroid Glands. Boston, MA, US.
2018. Thyroid Cancer Tumor Board Complications. Invited. Surgery of Thyroid and Parathyroid Glands. Boston, MA, US.
2018. Endocrine Oncology. Invited. Cleveland Clinic. Cleveland, OH, US.
2018. Diagnosis and Management of Advanced Thyroid Cancer. Invited. ATA Satellite Symposium. Chicago, IL, US.
2017. Medullary Thyroid Cancer. Invited. Global Academic Programs: Medical Education Program on Neuroendocrine Tumors: Thyroid Cancer. Houston, TX, US.
2017. Efficacy of Targeted Therapy in Resensitization to Radioactive Iodine (RAI) in Advanced Thyroid Cancer: The MD Anderson Experience. Conference. Global Academic Programs Conference. Houston, TX, US.
2017. Endocrine Oncology. Invited. Intensive Review of Endocrinology and Metabolism. Cleveland, OH, US.
2017. Thyroid Cancer Cases - The Good, the Bad and the Ugly. Invited. AACE 27th Annual Scientific & Clinical Congress. Boston, MA, US.
2017. Pitfalls and Advancements in the Management of Advanced Thyroid Cancer. Invited. AACE 27th Annual Scientific & Clinical Congress. Boston, MA, US.
2017. Multidisciplinary Approach to Endocrine Disease: MEN 2A and Hypoparathyroidism. Invited. The American Association of Clinical Endocrinologists (AACE) 26th Annual Meeting. Austin, TX, US.
2017. Malignant Struma Ovarii: a Case Series. Conference. The American Association of Clinical Endocrinologists (AACE) 26th Annual Meeting. Austin, TX, US.
2017. The Effects of Kinase Inhibitors on Body Composition in Endocrine Tumor Patients - Pilot Study. Conference. The Endocrine Society 99th Annual Meeting and Expo. Orlando, FL, US.
2017. Efficacy of Targeted Therapy in Resensitization of Radioactive Iodine (RAI) in Advanced Thyroid Cancer: The MD Anderson Experience. Conference. The Endocrine Society 99th Annual Meeting and Expo. Orlando, FL, US.
2016. A Multi-Center Phase II Study of Everolimus in Patients with Aggressive Thyroid Cancer and Genetic Analysis. Conference. 86th Annual Meeting of the American Thyroid Association (ATA). Denver, CO, US.
2016. Immunotherapy for Thyroid Cancer. Invited. 86th Annual Meeting of the American Thyroid Association (ATA). Denver, CO, US.
2016. Harvesting High-hanging Fruit: Targeted Therapy for BRAF mutant and BRAF wild-type Anaplastic Thyroid Cancer (ATC). Conference. American Thyroid Association, 86th Annual Meeting. Denver, CO, US.
2016. Multikinase Inhibitor Therapy: When to Pull the Trigger. Invited. Endocrine Society 98th Annual Meeting and Expo. Boston, MA, US.
2016. Targeted Therapy for Resensitization (or redifferentiation) of Thyroid Cancers to radioactive iodine (RAI) therapy: Perhaps a Promising Approach. Conference. 86th Annual Meeting of the American Thyroid Association. Denver, CO, US.
2015. ECD & Hormones. Invited. Erdheim-Chester Disease Global Alliance. Houston, TX, US.
2015. Thyroid Disorders: An update. Invited. National Arab American Medical Association. Houston, TX, US.
2015. Integrative Concepts in Endocrinology and Endocrine Surgery - A Tale of Two Cities. Invited. The American Association of Clinical Endocrinologists (AACE). Las Vegas, NV, US.
2015. Hands on with Multikinase Inhibitors for Advanced Thyroid Cancer. Invited. The American Association of Clinical Endocrinologists (AACE) 24th Annual Meeting. Tampa, FL, US.
2015. Management of Advancing and Progressive Thyroid Cancer. Invited. The American Association of Clinical Endocrinologists (AACE) 24th Annual Meeting. Tampa, FL, US.
2015. Medullary Thyroid Cancer. Invited. The American Association of Clinical Endocrinologists (AACE) 24th Annual Meeting. Tampa, FL, US.
2014. Parathyroid Cancer: New Treatments on the Horizon?. Invited. American College of Surgeons. San Francisco, CA, US.
2014. Is There an Alternative Treatment Option for Patients with Advanced Papillary Thyroid Cancer (PTC) Harboring the BRAFV600E Mutation?. Conference. Endocrine Society 96th Annual Meeting and Expo. Chicago, IL, US.
2014. Integrative Concepts in Endocrinology and Endocrine Surgery – A Tale of Two Cities. Invited. Endocrine Surgery Symposium. Las Vegas, NV, US.
2014. Systemic Therapy for Thyroid Cancer. Invited. Global Academic Programs. Seoul.
2013. Management of Poorly Differentiated/Anaplastic Carcinoma and Thyroid Lymphoma. Invited. 83rd Annual Meeting of the American Thyroid Association, Meet the Professor Workshop. San Juan, PR.
2013. Off Label use of Sorafenib in Patients with Differentiated Thyroid Cancer: Focus on Tolerability Profile. Conference. 83rd Annual Meeting of the American Thyroid Association. San Juan, PR.
2013. Survival and efficacy of tyrosine kinase inhibitors after first line sorafenib failure in patients with advanced differentiated thyroid cancer. Conference. 83rd Annual Meeting of the American Thyroid Association. San Juan, PR.
2013. Outcomes of patients with poorly differentiated thyroid cancer of follicular origin treated with first line sorafenib. Conference. 83rd Annual Meeting of the American Thyroid Association. San Juan, PR.
2013. Differentiated Thyroid Cancer, Medical Oncology Thyroid Cancer, Comprehensive Board Review in Hematology and Medical Oncology. Invited. Baylor College of Medicine and the University of Texas MD Anderson Cancer Center. Houston, TX, US.
2013. OR14-5 Salvage Therapy with Tyrosine Kinase Inhibitors (TKIs) for Differentiated Thyroid Carcinoma (DTC) After First Line Sorafenib Failure. Conference. Endocrine Society 95th Annual Meeting and Expo. San Francisco, CA, US.
2013. Salvage Therapy with Tyrosine Kinase Inhibitors for Differentiated Thyroid Carcinoma After First Line Sorafenib Failure. Conference. Endocrine Society 95th Annual Meeting and Expo. San Francisco, CA, US.
2013. Update in the Management of Anaplastic Thyroid Cancer (ATC); 2. Management of Thyroid Cancer Resistant to Conventional Therapy – Aggressive or Less Aggressive?. Invited. Thyroid Cancer Symposium. Phoenix, AZ, US.
2013. Current Medical Therapies for Advancing, Non-Iodine avid DTC. Invited. Thyroid Cancer Symposium. Phoenix, AZ, US.
2013. Case Management Discussions. Invited. Thyroid Cancer Symposium. Phoenix, AZ, US.
2012. Research - Round Table. Invited. 15th Annual Thyroid Cancer Survivors' Association (ThyCA) Conference. Itasca, IL, US.
2012. Seeking a Second Opinion, When it is Time? An Informal Discussion. Invited. 15th Annual Thyroid Cancer Survivors' Association (ThyCA) Conference. Itasca, IL, US.
2012. Thyroid Neoplasms Comprehensive Board Review in Hematology and Medical Oncology. Invited. Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Molecular Profiling of Advanced Thyroid Carcinomas. Conference. Endocrine Society 94th Annual Meeting and Expo. Houston, TX, US.
2012. Molecular Profiling of Advanced Thyroid Carcinomas. Invited. Endocrine Society 94th Annual Meeting and Expo. Houston, TX, US.
2012. Metabolic Toxicities from PI3K/AKT/MTOR pathway inhibitors. Invited. Toxicities and Symptoms of Cancer Therapy. Houston, TX, US.
2012. Symptoms and Toxicities in the Era of Novel Cancer Therapeutics. Invited. Toxicities and Symptoms of Cancer Therapy. Houston, TX, US.
2012. Metabolic Effects Associated with Anticancer Agents Targeting the PI3K-AKT-MTOR (PAM) Pathway. Invited. 2012 National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) Early Drug Development Meeting, Department of Health & Human Services. Rockville, MD, US.
2011. Molecular Analysis of Brain Metastases from Thyroid Carcinomas. Conference. 81st Annual Meeting of the American Thyroid Association (ATA). Indian Wells, CA, US.
2011. Advances in the Treatment of Differentiated Thyroid Cancer Survivors' Association. Invited. 14th Annual Thyroid Cancer Survivors' Conference (ThyCA). Los Angeles, CA, US.
2011. Thyroid Neoplasms Comprehensive Board Review in Hematology and Medical Oncology. Invited. Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. A phase II trial of the multi-targeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). Conference. Division of Internal Medicine Research Retreat, TX, US.
2011. Thyroid Cancer. Invited. 28th Annual Western Regional Oncology Conference. San Antonio, TX, US.
2010. Differentiated Thyroid Cancer: Newer Therapies. Invited. 13th Annual Thyroid Cancer Survivors' Conference (ThyCA). Dallas, TX, US.
2010. Endocrine Tumors Comprehensive Board Review in Hematology and Medical Oncology. Invited. Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. 4D Neck CT versus SPECT/CT Using Tc99m Sestamibi in the Localization of Parathyroid Adenomas: Which Study and When?. Conference. Endocrine Society 92nd Annual Meeting and Expo. San Diego, CA, US.
2010. Hyperglycemia, Hypertriglyceridemia, and Hypercholesterolemia in a Phase I Trial of the Combination of an mTOR Inhibitor and IGF-1 Receptor Inhibitor. Conference. American Society of Clinical Oncologists Annual Meeting (AACE) 19th Annual Meeting. Chicago, IL, US.
2009. Progressive Differentiated Thyroid Carcinoma-Beyond RAI. Invited. 12th Annual Thyroid Cancer Survivors' Association (ThyCa). Boston, MA, US.
2009. Metabolic Complications of PI3K, AKT, mTOR Inhibitor Investigational Drug Steering Committee Conference. Invited. Cancer Therapy Evaluation Program- NCI. Chicago, IL, US.
2009. Management of Hyperglycemia in Upper GI Cancers, Educational Session. Invited. American Association of Clinical Endocrinologists (AACE), 18th Annual Meeting. Orlando, FL, US.
2008. Endocrine Neoplasia Comprehensive Board Review in Hematology and Medical Oncology. Invited. Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2008. Meeting the Challenge of Co-Morbid Diabetes and Cancer. Invited. 3rd Oncology Nursing Symposium. Houston, TX, US.
2007. Benign Thyroid Goiter Presents with True Vocal Cord Paralysis. Conference. The American Association of Clinical Endocrinologists (AACE) 16th Annual Meeting. Orlando, FL, US.
2007. Diabetes and Cancer. Invited. 2nd Annual Nursing Symposium: Excellence Through Innovation, The University of Texas MD Anderson Cancer Center, US.
2007. Diabetes: Sweet on Cancer, Diabetes Mellitus in People with Serious Illnesses: Beyond Sick Day Guidelines. Invited. Mayo Clinic and The University of Texas MD Anderson Cancer Center - Joint Conference. Houston, TX, US.
2006. Papillary Thyroid Micro Carcinoma with Metastatic Spread to Bone. Conference. 76th Annual Meeting of the American Thyroid Association (ATA). Phoenix, AZ, US.

International Presentations

2025. Challenges in Management of Aggressive Thyroid Cancer. Invited. World Cancer Congress, Summit and Exhibition 2025. Muscat, OM.
2025. ATA Guidelines 2025 Thyroid Cancer. Invited. World Cancer Congress, Summit and Exhibition 2025. Muscat, OM.
2025. Improving Outcomes in Anaplastic Thyroid Cancer. Invited. World Congress on Thyroid Cancer. Boston, US.
2025. Advanced Thyroid Cancer Management: Neoadjuvant + Redifferentiation/Immune Rx. Panelist. World Congress on Thyroid Cancer. Boston, US.
2025. Integrating Immunotherapy in Thyroid Cancer Treatment. Invited. World Congress on Thyroid Cancer. Boston, US.
2025. Mechanisms of Development of Drug Resistance to Targeted Therapies. Invited. 17th International Thyroid Congress. Rio de Janeiro, BR.
2025. Parathyroid Cancer: The MD Anderson Experience. Invited. 19th WorldMEN Meeting. São Paulo, BR.
2024. Long term management of medullary thyroid cancer after surgery – how should I be followed and for how long?. Invited. 27th International Thyroid Cancer Survivors' Conference. Houston, US.
2024. Being your own patient advocate. Do I have the right medical team for my situation? Should I consider getting a second opinion? Do I need an oncologist for my care?. Invited. 27th International Thyroid Cancer Survivors' Conference. Houston, US.
2024. Difficult cases with the International Tumor Board. Invited. 46th Annual Meeting European Thyroid Association. Athens, GR.
2024. Redifferentiation in thyroid cancer: can we make a promise come true?. Invited. 46th Annual Meeting European Thyroid Association. Athens, GR.
2024. Updates and perspectives in the treatment of iodine-refractory thyroid cancer. Invited. IDOR 2024. Sao Paulo, BR.
2023. Ask a doctor your questions about medullary thyroid cancer. Conference. 26th Annual International Thyroid Cancer Survivors' Conference, US.
2023. Being your own patient advocate. Do I have the right medical team for my situation? Should I consider getting a second opinion? Do I need an oncologist for my care?. Conference. 26th Annual International Thyroid Cancer Survivors' Conference, US.
2022. Do I have the right medical team for my situation? Should I consider getting a second opinion? Do I need an oncologist for my care?. Invited. 25th International Thyroid Cancer Survivors’ Virtual Conference. Houston - Virtual, US.
2022. I've had surgery followed by radioactive iodine. Now I have non-avid (RAI resistant) disease. When should I consider biomarker testing to look for NTRK, RET and other therapeutic targets?. Invited. 25th International Thyroid Cancer Survivors' Virtual Conference. Houston - Virtual, US.
2022. Practical MTC Management. Invited. World Congress on Thyroid Cancer. Houston - Virtual, US.
2020. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). Highlighted Poster Discussion. Conference. ASCO Virtual Scientific Program, US.
2019. Recurrence Management Surgery and Non-Surgical Ablative Therapy: When? Why? How?. Invited. World Congress on Thyroid Cancer. Rome, US.
2019. Medullary Thyroid Cancer. Invited. World Congress on Thyroid Cancer. Rome, US.
2019. MTC Follow Up, Surveillance and Traditional Management. Invited. World Congress on Thyroid Cancer. Rome, IT.
2019. TKI Prevention and Management of Side Effects - Skin and CV. Invited. World Congress on Thyroid Cancer. Rome, IT.
2019. Targeted Therapies and Trials in Parathyroid Cancer. Invited. The University of Texas MD Anderson Cancer Center. Houston, US.
2018. Papillary and Follicular Thyroid Cancer: After Diagnosis, When and How to Treat, or When “Active Surveillance” or “Watch and Wait” Is An Option. Invited. 21st International Thyroid Cancer Survivors’ Conference (ThyCA). Chicago, US.
2017. Radioactive Iodine and Beyond. Invited. 60th Annual Meeting of the Japanese Thyroid Association. Beppu City, JP.
2017. Current Landscape in Medullary Thyroid Cancer – Update for Clinicians. Invited. Early Riser Satellite Symposium Presented by American Association of Clinical Endocrinologists (AACE). Victoria, CA.
2017. Emergence of V804M Resistance Gatekeeper Mutation in Sporadic Medullary Thyroid Carcinoma Patients Treated with TKI Tyrosine Kinase Inhibitors. Conference. 87th Annual Meeting of the American Thyroid Association. Victoria, CA.
2017. Other Adverse Events and Symptom Burden in Thyroid Cancer: How Well do we Measure and Manage this?. Invited. International Thyroid Oncology Group (ITOG). Durham, US.
2015. Treating Papillary and Follicular Thyroid Cancer. Radioactive Iodine, Targeted Therapy Drugs, and Clinical Trials. Invited. 18th International Thyroid Cancer Survivors' Conference (ThyCa). St. Louis, US.
2015. Papillary and Follicular Thyroid Cancer: After Diagnosis, When to Treat, and How, or When "Watch and Wait" is an Option. Invited. 18th International Thyroid Cancer Survivors' Conference (ThyCA). St. Louis, US.
2015. Evaluation of Thyroid Nodules. Invited. Egyptian Society of Endocrinology and Obesity (ESEO). Alexandria, EG.
2015. Clinical Trials in the Treatment of Metastatic Thyroid Cancer. Invited. Egyptian Society of Endocrinology and Obesity (ESEO). Alexandria, EG.
2013. Treatment of Distant Metastases: When Should a Patient Be Considered RAI Refractory?. Invited. 2nd World Congress on Thyroid Cancer. Toronto, CA.
2013. A Phase II study of Everolimus in Patients with aggressive RAI Refractory (RAIR) Thyroid cancer (TC). Conference. American Society of Clinical Oncology (ASCO). Chicago, US.
2011. New Drugs for the Treatment of Advanced Thyroid Cancer Refractory to Radioiodine Therapy. Invited. International Society of Oncology and Biomarkers. Florence, IT.
2011. Managing Diabetes in Patients with Cancer. Invited. Autumn Internal Medicine Update for Oncology Conference (AIM-UP). Toronto, CA.
2010. Sunitinib in Medullary Thyroid Cancer. Invited. 14th International Thyroid Congress. Paris, FR.
2010. Role of Cytotoxic Chemotherapy in Advanced Differentiated Thyroid Cancer: A Review of the MD Anderson Experience. Conference. 14th International Thyroid Congress. Paris, FR.
2009. Phase I Trial of Combination Sorafenib and Tipifarnib: Update on the Experience in Advanced Differentiated Thyroid Cancer (DTC) and Medullary Thyroid Cancer (MTC), Oral Presentation. Conference. World Congress on Thyroid Cancer. Toronto, CA.
2009. Detection of Recurrence of Differentiated Thyroid Cancer, Panelist & Speaker. Invited. World Congress on Thyroid Cancer. Toronto, CA.
2007. Oncologic Outcomes in Diabetic Patients with Colon Cancer. Conference. Endocrine Society 89th Annual Meeting and Expo. Toronto, CA.
2007. Hypocalcemia Induced by Bisphosphonates in Cancer Patients with Vitamin D Deficiency. Conference. Endocrine Society 89th Annual Meeting and Expo. Toronto, CA.

Formal Peers

2023. Management of Advanced Thyroid Cancer; Personalizing Therapy. Invited. Madison, WI, US.
2021. Systemic Therapy in Thyroid Cancer. Invited. Virtual, US.
2021. Meet the Professor. Invited. Virtual, US.
2021. TruthAboutTC Virtual Seminar. Invited. Houston, TX, US.
2018. TKI Therapy for Differentiated Thyroid Cancer. Invited. Stanford, CA, US.
2018. Differentiated Thyroid Cancer: RAI, System Therapies and Beyond. Invited. Dallas, TX, US.
2016. The Ira Rosenthal Memorial Lecturer Thyroid Cancer: Update of the new ATA Guidelines. Visiting. Chicago, IL, US.
2013. Thyroid Cancer Update. Invited. Houston, TX, US.
2011. Metastatic Differentiated Thyroid Cancer - Treatment Options in 2011. Invited, GB.
2011. Metabolic Effects of Targeted Therapies. Invited. Boston, MA, US.
2009. Treatment of Metastatic Thyroid Cancer Beyond Radioactive Iodine. Invited. New York, NY, US.
2009. Thyroid. Invited. Houston, TX, US.
2008. Management of Metastatic Thyroid Cancer. Invited, US.
2007. Thyroid Functional Abnormalities. Invited, US.
2007. Diabetes in the Cancer Patient. Invited, US.
2004. Diabetes: Sweet on Cancer. Invited. Muscat, Sultanate of Oman.
2004. Treatment of Differentiated Thyroid Carcinoma: An Update. Invited.
2004. Diabetes & Leukemia: The Untold Story. Invited, OM.
2003. Cancer and Diabetes, Endocrine Grand Rounds. Invited, US.

Less

Grant & Contract Support

Date:	2023 - Present
Title:	Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer
Funding Source:	NIH
Role:	PI
ID:	CA246553

Date:	2023 - Present
Title:	A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	PI

Date:	2023 - Present
Title:	A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer
Funding Source:	NIH/NCI
Role:	PI

Date:	2022 - Present
Title:	Presurgical Neoadjuvant Lenvatinib for Locally Invasive Thyroid Cancer
Funding Source:	Eisai, Inc
Role:	PI
ID:	2021-1173

Date:	2018 - 2020
Title:	A Combination Therapy for Cancer-Related Fatigue in Advanced Cancer Patients
Funding Source:	NIH/National Institute of Nursing Research
Role:	Co-I

Date:	2017 - 2018
Title:	Novel Pathways to Escape Targeted Therapies in Thyroid Cancers
Funding Source:	Elsa U Pardee Foundation
Role:	Other Significant Contributor

Date:	2017 - Present
Title:	Atezolizumab Combinations with Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Cancer
Funding Source:	Genentech, Inc
Role:	PI
ID:	8391517

Date:	2017 - 2021
Title:	1%, Atezolizumab Combinations with Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas
Funding Source:	Genentech Strategic Alliance
Role:	Co-PI
ID:	54267

Date:	2017 - 2017
Title:	Novel Alternative Pathways and Mutational Hotspots in Papillary Thyroid Cancer Acquired Resistance to BRAF Inhibitors
Funding Source:	American Thyroid Association
Role:	Other Significant Contributor

Date:	2015 - 2016
Title:	The impact of energy balance and the insulin/IGF axis on resistance to targeted therapy in melanoma
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Collaborator

Date:	2015 - 2017
Title:	Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors - Pilot Study
Funding Source:	MD Anderson
Role:	PI

Date:	2015
Title:	Physical Activity + Dexamethasone for Fatigue in Advanced Cancer
Funding Source:	American Cancer Society (ACS)
Role:	Co-I

Date:	2012 - 2023
Title:	A Randomized Phase 2 Study of Single agent GSK2118436 (BRAFi) vs. Combination Regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in Patients with BRAF Mutated thyroid Carcinoma
Funding Source:	National Comprehensive Cancer Network
Role:	PI

Date:	2011 - 2015
Title:	An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor R05185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine
Funding Source:	Roche
Role:	Co-I

Date:	2011 - 2013
Title:	A PI3K Based Phosphoproteome Signature to Predict Prognosis and Response to Therapy in BRAF Mutant Papillary Thyroid Carcinoma
Funding Source:	American Thyroid Association
Role:	PI

Date:	2010 - 2016
Title:	XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Solid Tumors
Funding Source:	Exelixis
Role:	Co-I
ID:	CS2010-00032297JW

Date:	2010 - 2020
Title:	A Phase II Trial Using RAD001 for Patients with Radioiodine Refractory Thyroid Cancer
Funding Source:	Novartis
Role:	PI
ID:	CS2010-00032235MA

Date:	2010
Title:	PI3K & BRAF Mutant Papillary Thyroid Cancer Center for Clinical & Translational Sciences Pilot Grant
Funding Source:	NIH
Role:	PI

Date:	2009 - 2018
Title:	A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Funding Source:	Bayer
Role:	PI
ID:	CS2010-00032234MA 01

Date:	2007 - 2012
Title:	Continuous Glucose Monitoring Device Compared with Point-of-Care Glucose Testing in the ICU
Funding Source:	The University of Texas System
Role:	PI

Date:	2007 - 2017
Title:	Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
Funding Source:	NCI
Role:	PI
ID:	NSC736511

Date:	2007 - 2009
Title:	Novel Tools for Predicting Development of Osteonecrosis of the Jaw: A Pilot Study
Funding Source:	Health Science Center Presidential Grant from Clinical Research and Evidence Based-Medicine
Role:	Co-I

Date:	2007
Title:	PAnCREaS: Pancreatic Adenocarcinoma and Regulation of Elevated Sugars
Funding Source:	K23 National Cancer Institute/ National Institutes of Health
Role:	PI

Date:	2007
Title:	A Masked Comparison Study of Continuous Glucose Monitoring and Fingerstick Glucose Monitoring: A Multi-Center Intensive Care Unit Study
Funding Source:	K12 Center for Clinical & Translational Sciences
Role:	PI

Date:	2006 - 2007
Title:	Follow-Up of Thyroid Cancer Patients from Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method
Funding Source:	Genzyme Corporation
Role:	Co-I

Date:	2005 - Present
Title:	Retrospective chart review of the clinical and laboratory features of Thyroid Carcinoma diagnosed or treated at The University of Texas M.D. Anderson Cancer Center
Funding Source:	The University of Texas M.D. Anderson Cancer Center
Role:	PI
ID:	RCR04-0933

Date:	2004 - 2008
Title:	Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy for Acute Lymphocytic Leukemia
Funding Source:	Novo Nordisk
Role:	PI

Date:	2004 - 2005
Title:	Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma
Funding Source:	Ohio State University Research Foundation
Role:	Co-I

Date:	2004 - 2006
Title:	Effect of Recombinant Human TSH on Utility of PET-CT Imaging for Patients with Differentiated Thyroid Carcinoma, CS2004-00011398LE
Funding Source:	Genzyme Corporation
Role:	Co-I

Date:	2004 - 2008
Title:	Diabetes and the Cancer Patient
Funding Source:	Multidisciplinary Research Program
Role:	Co-I

Title:	Approaches to Optimize Thyroid Cancer Detection and Therapy
Funding Source:	NIH SPORE/Ohio State University
Role:	Other Significant Contributor

Title:	Improving Risk Stratification and Treatment Response Prediction in Thyroid Cancer Through Incorporation of Molecular Markers and Clinical Data
Funding Source:	University of Utah
Role:	Other Significant Contributor

Title:	SPORE in Neuroendocrine Cancer at UAB - Project 3: Diagnostics-coupled CDK Targeted Treatments for Cancer
Funding Source:	NIH SPORE/University of Alabama Medical Center
Role:	PI

Title:	A PI3K Based Phosphoproteome Signature in Braf Mutant Papillary Thyroid Carcinoma, Head and Neck
Funding Source:	SPORE Grant
Role:	PI

Title:	Phase I Study of IMC-A12 (NSC# 742460) in Combination with Temsirolimus CCI-779
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Determining Prognosis of Therapy for Papillary Thyroid Carcinoma using a PI3 Kinase Pathway Signature, Institutional Research Grant
Funding Source:	American Cancer Society (ACS)
Role:	PI

Title:	Osteonecrosis Risk Assessment Longitudinal Study
Funding Source:	NIH/NIDCR
Role:	Co-I
ID:	R21

Selected Publications

Peer-Reviewed Articles

Maniakas A, Wilde DC, Fournier I, Hyde EK, Xu L, Wang JR, Gross ND, Sturgis EM, Banuchi V, Busaidy NL, Cabanillas ME, Iyer P, Dadu R, Waguespack SG, Hu MI, Gunn GB, Kwon M, Ahmed S, Williams MD, Zafereo ME. Segmental Tracheal Resection for Thyroid Cancer: Perioperative Morbidity, Locoregional Control, and Survival. Head Neck, 2025. e-Pub 2025. PMID: 41059669.
Fournier I, Bandi AV, Hamidi S, Iyer P, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Waguespack SG, Basmaci UN, Williams MD, Mansour M, Monroe MG, Gross ND, Goepfert RP, Perrier ND, Banuchi V, Wang JR, Maniakas A, Zafereo ME. Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer. Head Neck, 2025. e-Pub 2025. PMID: 40891104.
Hawes EE, Banuchi VE, Maniakas A, Wang JR, Graham PH, Diersing JD, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Waguespack SG, Ahmed S, Alizada S, Belcastro A, Alsharif R, Hu MI, Zafereo ME. Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques. Head Neck, 2025. e-Pub 2025. PMID: 40747656.
Haddad, RI, Bischoff, L, Applewhite, MK, Bernet, VJ, Blomain, E, Brito, M, Busaidy, NL, Campbell, MJ, Delozier, O, Duh, QY, Ehya, H, Grady, E, Guo, T, Haymart, M, Hunt, JP, Kandeel, F, Kotwal, A, Lamonica, D, Lorch, J, Mandel, SJ, Markovina, S, Mydlarz, WK, Nabell, LM, Raeburn, CD, Rezaee, R, Ridge, JA, Ritter, H, Roth, MY, Agosto, S, Scheri, RP, Shah, JP, Sipos, J, Sippel, RS, Sturgeon, C, Wirth, L, Wong, RJ, Worden, F, Yeh, M, Darlow, S, Cassara, CJ, Sliker, B. Thyroid Carcinoma, Version 1.2025 Featured Updates to the NCCN Guidelines®. JNCCN Journal of the National Comprehensive Cancer Network 23(7), 2025. e-Pub 2025. PMID: 40639400.
Cabanillas, ME, Busaidy, NL, Gunn, GB, Iyer, PC, Ferrarotto, R, Gule-Monroe, MK, Maniakas, A, Williams, MD, Liu, S, Fellman, B, Spiotto, MT, Hamidi, S, Akhave, NS, Lee, A, Wang, RJ, De Sousa, LG, Marczyk, VR, Zafereo, M, Dadu, R. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid 35(7):763-770, 2025. e-Pub 2025. PMID: 40609521.
Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, Ferrarotto R, Guise TA, Hofmann MC, Hosseini SM, Hu MI, Iyer PC, Mansour M, Marczyk VR, Roy-Chowdhuri S, Sherman SI, Sousa LG, Wang JR, Williams MD, Zafereo ME, Waguespack SG, Cabanillas ME. Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues. J Clin Endocrinol Metab, 2025. e-Pub 2025. PMID: 40568752.
Hamidi, S, Dadu, R, Iyer, PC, Busaidy, NL, Maniakas, A, Wang, RJ, Banuchi, VE, Hosseini, SM, Williams, MD, Zafereo, M, Cabanillas, ME. Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid Cancer. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40570261.
Cabanillas, ME, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Gunn, GB, Hamidi, S, Hofmann, M, Hosseini, SM, Iyer, PC, Lai, SY, Lee, A, Maniakas, A, Ning, M, Spiotto, MT, Wang, RJ, Williams, MD, Zafereo, M. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer. Thyroid 35(5):462-470, 2025. e-Pub 2025. PMID: 40388579.
Houl JH, Bagheri-Yarmand R, Kunnimalaiyaan M, Miranda Mendez P, Kidd JL, Dadbin A, Jurado Ruiz A, Parekh PA, Henderson YC, Chari NS, Thennavan AT, Powell RT, Stephan CC, Zhao X, Maniakas A, Nurieva R, Busaidy NL, Cabanillas ME, Dadu R, Zafereo M, Wang JR, Lai SY, Hofmann MC. Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells. bioRxiv, 2025. e-Pub 2025. PMID: 40027641.
Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
Yennurajalingam S, Valero V, Smalgo BG, Overman MJ, Dasari A, Wolff RA, Raghav KPS, Barcenas CH, Busaidy NL, Fellman B, Basen-Engquist K, Hess KR, Tripathy D, Bruera E. Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial. J Natl Compr Canc Netw 23(1), 2025. e-Pub 2025. PMID: 39773433.
Bronk, JK, Augustyn, A, Mohamed, AS, Fuller, C, Garden, AS, Moreno, AC, Lee, A, Morrison, WH, Phan, J, Reddy, JP, Rosenthal, DI, Spiotto, MT, Frank, SJ, Dadu, R, Busaidy, NL, Zafereo, M, Wang, RJ, Maniakas, A, Ferrarotto, R, Iyer, PC, Cabanillas, ME, Gunn, GB. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiotherapy and Oncology 202, 2025. e-Pub 2025. PMID: 39489425.
Dudzinski SO, Cabanillas ME, Hamidi S, Marczyk VR, Busaidy NL, Dadu R, Welsh J, Hu MI, Gunn GB, Wang C, Waguespack SG, Phan J, Beckham TH, Chang JY, Sherman SI, Reddy JP, Ying AK, O'Reilly MS, Chen A, Lee A, Gandhi SJ, Liao Z, Ludmir EB, Nguyen QN, Lin SH, Zafereo ME, Ning MS. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral. J Natl Compr Canc Netw 23(1), 2024. e-Pub 2024. PMID: 39662038.
Hamidi S, Yedururi S, Hu MI, Busaidy NL, Sherman SI, Jimenez C, Grubbs EG, Maniakas A, Zafereo ME, Subbiah V, Waguespack SG. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid 35(1):6-17, 2024. e-Pub 2024. PMID: 39630530.
Dagher SA, Learned KO, Dagher R, Wang JR, Zhao X, Hosseini SM, Maniakas A, Cabanillas ME, Busaidy NL, Dadu R, Iyer P, Zafereo ME, Khalaf AM. [18F]-Fluorodeoxyglucose Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma Following BRAF-Targeted Therapy. AJNR Am J Neuroradiol 46(6):1260-1267, 2024. e-Pub 2024. PMID: 39572200.
Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol 10(12):1672-1680, 2024. e-Pub 2024. PMID: 39446377.
Feldman HA, Busaidy NL, Tame-Elorduy A, Silva AK, Halfteck G, Merriman K, Waguespack SG, Graham PH, Williams MD, Perrier ND. Clinical course of atypical parathyroid neoplasm with soft tissue extension. J Surg Oncol 130(5):1092-1096, 2024. e-Pub 2024. PMID: 39155668.
Hensley SG, Hu MI, Bassett RL, Ying AK, Zafereo ME, Perrier ND, Busaidy NL, Hyde SM, Grubbs EG, Waguespack SG. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades. J Clin Endocrinol Metab 109(9):2256-2268, 2024. e-Pub 2024. PMID: 38441533.
Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn GB, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini SM, Busaidy NL, Cabanillas ME. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol 10(9):1264-1271, 2024. e-Pub 2024. PMID: 38990526.
Mongare N, Orare K, Busaidy NL, Sokwala A, Opio C. Plasma Exchange for Refractory Pruritus Due to Drug-Induced Chronic Cholestasis Following Azithromycin Misuse in COVID-19 Infection. Cureus 16(5):e60884, 2024. e-Pub 2024. PMID: 38910696.
Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier N, Brown S, Holla VR, Dadu R, Busaidy NL, Sherman SI, Cabanillas M, Waguespack SG, Zafereo ME, Grubbs EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. J Endocr Soc 8(6):bvae048, 2024. e-Pub 2024. PMID: 38660141.
Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Wang JR, Busaidy NL, Cabanillas ME. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 34(3):336-346, 2024. e-Pub 2024. PMID: 38226606.
Maniakas A, Sullivan A, Hu MI, Busaidy NL, Cabanillas ME, Dadu R, Waguespack SG, Fisher SB, Graham PH, Gross ND, Grubbs EG, Perrier ND, Wang JR, Gunn B, Garden AS, Megahed R, Navuluri S, Li X, Williams MD, Zafereo M. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck 46(2):328-335, 2024. e-Pub 2024. PMID: 38009416.
Szabo Yamashita, T, Shirali, AS, Meas, S, Sarli, VN, Clemente-Gutierrez, U, Chiang, YJ, Silva-Figueroa, A, Vodopivec, DM, Williams, MD, Fisher, SB, Graham, PH, Grubbs, EG, Lucci, A, Busaidy, NL, Perrier, ND. Is there a role for liquid biopsy in the surveillance of parathyroid carcinoma?. Surgery (United States) 175(1):193-198, 2024. e-Pub 2024. PMID: 37993289.
Lu L, Wang JR, Henderson YC, Bai S, Yang J, Hu M, Shiau CK, Pan T, Yan Y, Tran TM, Li J, Kieser R, Zhao X, Wang J, Nurieva R, Williams MD, Cabanillas ME, Dadu R, Busaidy NL, Zafereo M, Navin N, Lai SY, Gao R. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J Clin Invest 133(11), 2023. e-Pub 2023. PMID: 37053016.
Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo ME. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid 33(4):484-491, 2023. e-Pub 2023. PMID: 36762947.
Busaidy NL, Leung AM, Papaleontiou M. Celebrating 20 Years of Women in Thyroidology in the American Thyroid Association. Thyroid 33(3):271-272, 2023. e-Pub 2023. PMID: 36641640.
Shenson JA, Zafereo ME, Lee M, Contrera KJ, Feng L, Boonsripitayanon M, Gross N, Goepfert R, Maniakas A, Wang JR, Grubbs L, Vaporciyan A, Hofstetter W, Swisher S, Mehran R, Rice D, Sepesi B, Antonoff M, Cabanillas M, Busaidy NL, Dadu R, Silver NL. Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancer. Head Neck 45(3):547-554, 2023. e-Pub 2023. PMID: 36524701.
Maniakas A, Wilde DC, Hyde EK, Xu L, Wang JR, Gross ND, Busaidy NL, Cabanillas ME, Iyer P, Dadu R, Gunn GB, Garden AS, Kwon M, Ahmed S, Williams MD, Zafereo ME. Segmental tracheal resection for thyroid cancer: Perioperative morbidity, locoregional control, and survival. 11th International Conference on Head and Neck Cancer, 2023. e-Pub 2023.
Chen YH, Cabanillas M, Sperling J, Xu L, Goswami M, Maniakas A, Williams MD, Lai SY, Busaidy NL, Dadu R, Zafereo ME, Wang JR. Prior thyroid and non-thyroid cancer history do not significantly alter overall survival in patients diagnosed with anaplastic thyroid carcinoma. Thyroid 33(3):321-329, 2023. e-Pub 2023. PMID: 36511380.
Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid 33(1):129-132, 2023. e-Pub 2023. PMID: 36503246.
Cabanillas ME, Busaidy NL, Sherman SI. Redifferentiation therapy-Returning to our roots in a post-kinase inhibitor world. Clin Cancer Res 28(19):4164-4166, 2022. e-Pub 2022. PMID: 35895318.
Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid 32(10):1184-1192, 2022. e-Pub 2022. PMID: 35658604.
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(8):925-951, 2022. e-Pub 2022. PMID: 35948029.
Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol 6:e2100504, 2022. e-Pub 2022. PMID: 35977347.
Waguespack SG, Tewari SO, Busaidy NL, Zafereo ME. Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?. JCO Precis Oncol 6:e2100467, 2022. e-Pub 2022. PMID: 35420905.
Yennurajalingam S, Valero V, Lu Z, Liu DD, Busaidy NL, Reuben JM, Diaz Fleming C, Williams JL, Hess KR, Basen-Engquist K, Bruera E. Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial. J Natl Compr Canc Netw 20(3):1-9, 2022. e-Pub 2021. PMID: 34965510.
Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy NL, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep 12(1):1248, 2022. e-Pub 2022. PMID: 35075200.
Maniakas A, Henderson YC, Hei H, Peng S, Chen Y, Jiang Y, Ji S, Cardenas M, Chiu Y, Bell D, Williams MD, Hofmann MC, Scherer SE, Wheeler DA, Busaidy NL, Dadu R, Wang JR, Cabanillas ME, Zafereo M, Johnson FM, Lai SY. Novel anaplastic thyroid cancer PDXs and cell lines: Expanding preclinical models of genetic diversity. J Clin Endocrinol Metab 106(11):e4652-e4665, 2021. e-Pub 2021. PMID: 34147031.
Busaidy NL, Bagheri-Yarmand R, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, Shah MH, Ringel MD, Hofmann MC. RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers (Basel) 13(19), 2021. e-Pub 2021. PMID: 34638434.
Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid 31(8):1235-1243, 2021. e-Pub 2021. PMID: 33599171.
Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer 28(7):419-431, 2021. e-Pub 2021. PMID: 33890870.
Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy NL, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck 43(1):E7-E12, 2021. e-Pub 2021. PMID: 33169506.
Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR Jr, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. e-Pub 2020. PMID: 33097651.
Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid, 2020. e-Pub 2020. PMID: 32216548.
Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol, 2020. e-Pub 2020. PMID: 32761153.
Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck 42(6):1325-1328, 2020. e-Pub 2020. PMID: 32437031.
Zafereo M, McIver B, Vargas-Salas S, Domínguez JM, Steward DL, Holsinger FC, Kandil E, Williams M, Cruz F, Loyola S, Solar A, Roa JC, León A, Droppelman N, Lobos M, Arias T, Kong CS, Busaidy N, Grubbs EG, Graham P, Stewart J, Tang A, Wang J, Orloff L, Henríquez M, Lagos M, Osorio M, Schachter D, Franco C, Medina F, Wohllk N, Diaz RE, Veliz J, Horvath E, Tala H, Pineda P, Arroyo P, Vasquez F, Traipe E, Marín L, Miranda G, Bruce E, Bracamonte M, Mena N, González HE. A thyroid genetic classifier correctly predicts benign nodules with indeterminate cytology: two-independent multicenter, prospective validation trials. Thyroid 30(5):704-712, 2020. e-Pub 2020. PMID: 31910118.
Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. Surgery 167(1):80-86, 2020. e-Pub 2020. PMID: 31648931.
Silva-Figueroa AM, Bassett R, Christakis I, Moreno P, Clarke CN, Busaidy NL, Grubbs EG, Lee JE, Perrier ND, Williams MD. Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms. Endocr Pathol 30(4):285-296, 2019. e-Pub 2019. PMID: 31734935.
Asare EA, Silva-Figueroa A, Hess KR, Busaidy N, Graham PH, Grubbs EG, Lee JE, Williams MD, Perrier ND. Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center. Ann Surg Oncol, 2019. e-Pub 2019. PMID: 31111352.
Gan Q, Edeiken BS, Chen MM, Grubbs EG, Busaidy NL, Zafereo M, Perrier ND, Gule-Monroe MD, Krishnamurthy S. Utility of subcategorization of atypia of undetermined significance/follicular lesion of undetermined significance category in ultrasound-guided thyroid fine-needle aspiration in a large referral cancer center. J Am Soc Cytopathol, 2019. e-Pub 2019. PMID: 31526696.
Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 29(8):1036-1043, 2019. e-Pub 2019. PMID: 31319771.
Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck 41(6):1928-1934, 2019. e-Pub 2019. PMID: 30758123.
Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC, Morris LGT, Odell M, Scharpf J, Shaha A, Shin JJ, Shonka DC, Thompson GB, Tuttle RM, Urken ML, Wiseman SM, Wong RJ, Randolph G. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head Neck 41(4):843-856, 2019. e-Pub 2019. PMID: 30561068.
Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM, Esmaeli B. Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. Ophthalmic Plast Reconstr Surg 35(1):50-52, 2019. e-Pub 2019. PMID: 29927883.
Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw 16(12):1429-1440, 2018. e-Pub 2018. PMID: 30545990.
Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 35135166.
Silva-Figueroa A, Villalobos P, Williams MD, Bassett RL, Clarke CN, Lee JE, Perrier ND, Busaidy NL. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Surgery 164(5):960-964, 2018. e-Pub 2018. PMID: 30033186.
Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy NL, Cabanillas ME, Dadu R, Sherman S, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier ND, Sturgis EM, Zafereo ME. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid 28(10):1301-1310, 2018. e-Pub 2018. PMID: 30141373.
Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid 28(10):1243-1251, 2018. e-Pub 2018. PMID: 30132401.
Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab 103(10):3698-3705, 2018. e-Pub 2018. PMID: 30032208.
Amit M, Boonsripitayanon M, Goepfert RP, Tam S, Busaidy NL, Cabanillas ME, Dadu R, Varghese J, Waguespack SG, Gross ND, Graham P, Williams MD, Sturgis EM, Zafereo ME. Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?. Ann Surg Oncol 25(11):3380-3388, 2018. e-Pub 2018. PMID: 30022274.
Clarke CN, Katsonis P, Hsu TK, Koire AM, Silva-Figueroa A, Christakis I, Williams MD, Kutahyalioglu M, Kwatampora L, Xi Y, Lee JE, Kopetz ES, Busaidy NL, Perrier ND, Lichtarge O. Comprehensive Genomic Characterization of Parathyroid Cancer Identifies Novel Candidate Driver Mutations and Core Pathways. J Endocr Soc 3(3):544-559, 2018. e-Pub 2018. PMID: 30788456.
Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, Duh QY, Wong R, Sabra MM, Fagin JA, McIver B, Bernet VJ, Harrell RM, Busaidy N, Cibas ES, Faquin WC, Sadow P, Baloch Z, Shindo M, Orloff L, Davies L, Randolph GW. AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Head Neck 40(9):1881-1888, 2018. e-Pub 2018. PMID: 29947030.
Tam S, Amit M, Boonsripitayanon M, Busaidy NL, Cabanillas ME, Waguespack SG, Gross ND, Grubbs EG, Williams MD, Lai SY, Sturgis EM, Zafereo ME. Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid 28(8):982-990, 2018. e-Pub 2018. PMID: 29936892.
Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29(8):1869-1876, 2018. e-Pub 2018. PMID: 29912274.
Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):68, 2018. e-Pub 2018. PMID: 29996921.
Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid 28(7):945-951, 2018. e-Pub 2018. PMID: 29742974.
Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol 25(5):1395-1402, 2018. e-Pub 2018. PMID: 29427212.
Busaidy NL, Hannah GJ, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res 24(7):1546-1553, 2018. e-Pub 2018. PMID: 29301825.
Amit M, Tam S, Boonsripitayanon M, Cabanillas ME, Busaidy N, Grubbs EG, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer. JAMA Otolaryngol Head Neck Surg 144(2):108-114, 2018. e-Pub 2018. PMID: 29192312.
Iyer PC, Dadu R, Ferrarotto R, Busaidy N, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid 28(1):79-87, 2018. e-Pub 2018. PMID: 29161986.
Tam S, Amit M, Boonsripitayanon M, Cabanillas ME, Busaidy N, Gunn GB, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. JAMA Otolaryngol Head Neck Surg 143(12):1244-1251, 2017. e-Pub 2017. PMID: 29098272.
Duh QY, Busaidy N, Rahilly-Tierney C, Gharib H, Randolph G. A Systematic Review of the Methods of Diagnostic Accuracy Studies of the Afirma Gene Expression Classifier. Thyroid 27(10):1215-1222, 2017. e-Pub 2017. PMID: 28741442.
Christakis I, Vu T, Chuang HH, Fellman B, Figueroa AMS, Williams MD, Perrier ND, Busaidy NL. The Diagnostic Accuracy of Neck Ultrasound, 4D-Computed Tomography and Sestamibi Imaging in Parathyroid Carcinoma. European Journal of Radiology 95:82-88, 2017. e-Pub 2017. PMID: 28987702.
Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy N, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-3599, 2017. e-Pub 2017. PMID: 28911154.
Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy N, Ying AK, Yiin YH, William WN, Lu C, Lai SY. Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck 39(7):1291-1295, 2017. e-Pub 2017. PMID: 28452157.
Christakis I, Silva AM, Williams MD, Garden A, Grubbs EG, Busaidy N, Lee JE, Perrier ND, Zafereo M. Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. Pract Radiat Oncol, 2017. e-Pub 2017. PMID: 28751227.
Rao SN, Zafereo M, Dadu R, Busaidy N, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid 27(5):672-681, 2017. e-Pub 2017. PMID: 28068873.
Silva-Figueroa AM, Hess KR, Williams MD, Clarke CN, Christakis I, Graham PH, Grubbs EG, Lee JE, Perrier ND, Busaidy NL. Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma. J Am Coll Surg, 2017. e-Pub 2017. PMID: 28427885.
Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME. Real-time Genomic Characterization Utilizing Circulating Cell-free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid 27(1):81-87, 2017. e-Pub 2017. PMID: 27785980.
Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):jc20162815, 2016. e-Pub 2016. PMID: 27662441.
Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer. J Clin Endocrinol Metab 101(11):jc20162567, 2016. e-Pub 2016. PMID: 27575943.
Christakis I, Silva AM, Kwatampora LJ, Warneke CL, Clarke CN, Williams MD, Grubbs EG, Lee JE, Perrier ND, Busaidy NL. Oncologic progress for the treatment of parathyroid carcinoma is needed. J Surg Oncol 114(6):708-713, 2016. e-Pub 2016. PMID: 27753088.
Christakis I, Qiu W, Silva Figueroa AM, Hyde S, Cote GJ, Busaidy NL, Williams M, Grubbs E, Lee JE, Perrier ND. Clinical Features, Treatments, and Outcomes of Patients with Thymic Carcinoids and Multiple Endocrine Neoplasia Type 1 Syndrome at MD Anderson Cancer Center. Horm Cancer 7(4):279-87, 2016. e-Pub 2016. PMID: 27311764.
Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Arch Dermatol Res 308(5):357-65, 2016. e-Pub 2016. PMID: 27098388.
Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol 78(1):167-71, 2016. e-Pub 2016. PMID: 27286994.
Christakis I, Busaidy NL, Cote GJ, Williams MD, Hyde SM, Silva Figueroa AM, Kwatampora LJ, Clarke CN, Qiu W, Lee JE, Perrier ND. Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinico-pathologic challenge. The MD Anderson case series and review of the literature. Int J Surg 31:10-6, 2016. e-Pub 2016. PMID: 27212590.
Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine 51(2):351-9, 2016. e-Pub 2016. PMID: 26206754.
Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology 90(6):339-46, 2016. e-Pub 2016. PMID: 27207748.
Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid 25(10):1085-90, 2015. e-Pub 2015. PMID: 26200040.
Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw 13(9):1140-50, 2015. e-Pub 2015. PMID: 26358798.
Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients with Advanced Cancer Receiving Combination Treatment with the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist 20(7):737-41, 2015. e-Pub 2015. PMID: 26054632.
Recondo G, Busaidy N, Erasmus J, Williams MD, Johnson FM. Spindle epithelial tumor with thymus-like differentiation: A case report and comprehensive review of the literature and treatment options. Head Neck 37(5):746-54, 2015. e-Pub 2015. PMID: 24677409.
Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE, Lu X, Lu H, Meric-Bernstam F, Mills GB, Palmer G, Perrier ND, Scott KL, Shaw KR, Waguespack SG, Williams MD, Yelensky R, Cote GJ. RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab 100(3):788-93, 2015. e-Pub 2015. PMID: 25546157.
Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and Tolerability of Vemurafenib in Patients with BRAF(V600E) -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. J Clin Endocrinol Metab 100(1):jc20142246, 2015. e-Pub 2015. PMID: 25353071.
Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, Lavis V. Safe and effective dosing of Basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, Doxorubicin, vincristine, and dexamethasone chemotherapy. Diabetes Technol Ther 16(12):874-9, 2014. e-Pub 2014. PMID: 25321387.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ, DECISION investigators Busaidy N. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319-28, 2014. e-Pub 2014. PMID: 24768112.
Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by Age and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk Germline RET Proto-Oncogene Mutations. Thyroid 24(7):1096-106, 2014. e-Pub 2014. PMID: 24617864.
Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM. Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes. JAMA Otolaryngol Head Neck Surg 140(5):410-5, 2014. e-Pub 2014. PMID: 24700275.
Shawa H, Elsayes KM, Javadi S, Morani A, Williams MD, Lee JE, Waguespack SG, Busaidy NL, Vassilopoulou-Sellin R, Jimenez C, Habra MA. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol (Oxf) 80(3):342-7, 2014. e-Pub 2014. PMID: 24033606.
Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther 13(1):221-9, 2014. e-Pub 2014. PMID: 24170769.
Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C. Adrenocortical Carcinoma: Clinical Outcomes and Prognosis of 330 Patients at a Tertiary Care Center. European Journal of Endocrinology 169(9):891-899, 2013. e-Pub 2013. PMID: 24086089.
Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor Marker and Measurement Fluctuations May Not Reflect Treatment Efficacy in Patients with Medullary Thyroid Carcinoma on Long-Term RET Inhibitor Therapy. Ann Oncol 24(9):2256-61, 2013. e-Pub 2013. PMID: 23676418.
Lee S, Skelton TS, Zheng F, Schwartz KA, Perrier ND, Lee JE, Bassett RL, Ahmed S, Krishnamurthy S, Busaidy NL, Grubbs EG. The Biopsy-proven Benign Thyroid Nodule: Is Long-term Follow-up Necessary?. Journal of the American College of Surgeons 217(1):81-8, 2013. e-Pub 2013. PMID: 23659946.
Shawa H, Busaidy NL, Schellingerhout D, Habra MA. Unilateral Renal Artery Stenosis with Renal Atrophy in a Patient with Metastatic Papillary Thyroid Carcinoma Treated with Sorafenib. BMJ Case Report, 2013. e-Pub 2013. PMID: 23682094.
Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 12(5):355-62, 2012. e-Pub 2012. PMID: 22658895.
Busaidy N, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30(23):2919-28, 2012. e-Pub 2012. PMID: 22778315.
Del Fabbro E, Dev R, Cabanillas ME, Busaidy N, Rodriguez EC, Bruera E. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother 24(4):221-5, 2012. e-Pub 2012. PMID: 23040687.
Morris GS, Landry CL, Grubbs EG, Jimenez C, Busaidy NL, Perrier ND. Greater than age-predicted functional deficits in older patients with primary hyperparathyroidism. Endocr Pract 18(4):450-5, 2012. e-Pub 2012. PMID: 22784831.
Busaidy N, Cabanillas ME. Differentiated Thyroid Cancer: Management of Patients with Radioiodine Non-Responsive Disease. J Thyroid Res 2012:618985, 2012. e-Pub 2012. PMID: 22530159.
Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer 117(19):4381-9, 2011. e-Pub 2011. PMID: 21412758.
Khan MI, Habra MA, McCutcheon IE, Nogueras-González GM, Devin JK, Busaidy NL, Levine NB, Lindstrom W, Kagan D, Jimenez C, Waguespack SG. Random postoperative day 3 cortisol as a predictor of hypothalamic-pituitary-adrenal axis integrity after transsphenoidal surgery. Endocr Pract 17(5):1-25, 2011. e-Pub 2011. PMID: 21454228.
Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer. Clin Cancer Res 17(18):6052-60, 2011. e-Pub 2011. PMID: 21750201.
Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET Kinases Pathways with the Combination of the Multikinases Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifamib in Medullary and Differentiated Thyroid Malignancies. J Clin Endocrinol Metab 96(4):997-1005, 2011. e-Pub 2011. PMID: 21289252.
Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. J Clin Endocrinol Metab 96(3):717-25, 2011. e-Pub 2011. PMID: 21190975.
Landry CS, Grubbs EG, Busaidy NL, Monroe BJ, Staerkel GA, Perrier ND, Edeiken-Monroe BS. Cystic Lymph Nodes in the Lateral Neck are an Indicator of Metastatic Papillary Thyroid Cancer. Endocr Pract 17(2):240-4, 2011. e-Pub 2011. PMID: 20713342.
Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:985780, 2011. e-Pub 2011. PMID: 22007339.
Ayala-Ramirez M, Habra MA, Busaidy N, Cote G, Rich T, Waguespack S, Jimenez C. A Catecholamine Crisis on Mount Kilimanjaro: A Hypoxia Effect?. J Travel Med 31(3):424-6, 2010. e-Pub 2010. PMID: 21050326.
Morris GS, Grubbs EG, Hearon CM, Gantela S, Lee JE, Evans DB, Holmes HM, Busaidy NL, Jimenez C, Perrier ND. Parathyroidectomy Improves Functional Capacity in "Asymptomatic" Older Patients with Primary hyperparathyroidism: A Randomized Control Trial. Ann Surg Onc 251(5):832-7, 2010. e-Pub 2010. PMID: 20395857.
Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: The University of Texas MD Anderson Experience. J Clin Endocrinol Metab 95(6):2588-95, 2010. e-Pub 2010. PMID: 20392874.
Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, Randomized, Controlled Trial of Parathyroidectomy versus Observation in Patients with "Asymptomatic" Primary Hyperparathyroidism. Surgery 146(6):1116-22, 2009. e-Pub 2009. PMID: 19879613.
Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants After Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal. J Clin Endocrinol Metab 94(11):4171-9, 2009. e-Pub 2009. PMID: 19850694.
Williams MD, Suliburk JW, Staerkel GA, Busaidy NL, Clayman GL, Evans DB, Perrier ND. Clinical Significance of Distinguishing Between Follicular Lesion and Follicular Neoplasm in Thyroid Fine-Needle Aspiration Biopsy. Ann Surg Oncol 16(11):3146-53, 2009. e-Pub 2009. PMID: 19727961.
Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy NL, Markman M, Sherman SI, Kurzrock R. Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The University of Texas MD Anderson Cancer Center Experience. J Clin Endocrinol Metab 94(11):4423-32, 2009. e-Pub 2009. PMID: 19820016.
Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation Before 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer. J Clin Endocrinol Metab 94(4):1310-6, 2009. e-Pub 2009. PMID: 19158200.
Perrier ND, Edeiken B, Nunez R, Gayed I, Jimenez C, Busaidy NL, Potylchansky E, Kee S, Vu T. A Novel Nomenclature to Classify Parathyroid Adenomas. World J Surg 33(3):412-6, 2009. e-Pub 2009. PMID: 19148701.
Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth Factor Receptors Expression in Anaplastic Thyroid Carcinoma: Potential Markers for Therapeutic Stratification. Hum Pathol 39(1):15-20, 2008. e-Pub 2008. PMID: 17949783.
Stava CJ, Beck ML, Feng L, Lopez A, Busaidy NL. Diabetes Mellitus Among Cancer Survivors. Journal of Cancer Survivorship 1(2):108-15, 2007. e-Pub 2007. PMID: 18648951.
Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy NL, Klein MJ, Sherman SI, Shah MH. Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma. J Clin Endocrinol Metab 91(6):2201-4, 2006. e-Pub 2006. PMID: 16522694.
Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. J Clin Endocrinol Metab 91(3):926-32, 2006. e-Pub 2006. PMID: 16384850.
Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Jr, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid Carcinoma: A 22-Year Experience. Head Neck 26(8):716-26, 2004. e-Pub 2004. PMID: 15287039.
Shepler TR, Sherman SI, Faustina MM, Busaidy NL, Ahmadi MA, Esmaeli B. Nasolacrimal Duct Obstruction Associated with Radioactive Iodine Therapy for Thyroid Carcinoma. Ophthal Plast Reconstr Surg 19(6):479-81, 2003. e-Pub 2003. PMID: 14625496.
Cabanillas ME, Busaidy N, Iyer P, Wang JR, Hu MI, Zafereo M, Ferrarotto R, Lee A, Liu S, Gunn B, Spiotto M, Hamidi S, Akhave N, Sousa L, Maniakas A, Williams M, Banuchi V, Hosseini S, Dadu R. Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in anaplastic thyroid cancer (ATC): a phase 2, single center trial. American Thyroid Association.
Randolph G, Russell M, Ahmed AA, Sadow P, Shi R, ONeill A, Wong R, Sherman E, Ho A, Fagin J, Busaidy NL, Zafereo M, Wirth L. Results of a Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Differentiated Thyroid Cancer. American Thyroid Association.
Zafereo M, Cabanillas ME, Maniakas A, Wang JR, Chinn SB, Mady LJ, Fisher SB, Graham PH, Grubbs EG, Seim NB, Banuchi VE, Gule-Monroe M, Williams MD, Xu L, Busaidy NL, Dadu R, Hamidi S, Iyer PC, Waguespack SG, Sherman SI, Nabha FA, Ball DW, Worden FP, Hu MI. Neoadjuvant Treatment With Selpercatinib for RET-Altered Thyroid Cancer: A Multicenter Phase 2 Clinical Trial. American Thyroid Association.

Invited Articles

Busaidy N. The Year in Medical Thyroidology Review: Current Challenges and Future Directions. Thyroid, 2020. e-Pub 2020. PMID: 31842716.
Ibrahim EY, Busaidy NL. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer. Curr Opin Oncol 29(2):151-158, 2017. e-Pub 2017. PMID: 28141684.
Cabanillas M, Busaidy N, Kahn SA, Gunn GB, Dadu R, Rao SN, Waguespack SG. Molecular Diagnostics and Anaplastic Thyroid Carcinoma: The Time has Come to Harvest the High Hanging Fruit. International Journal of Endocrine Oncology, 2016. e-Pub 2016.
Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy N, Charnsangavej C. Current Update on Medullary Thyroid Carcinoma. AJR Am J Roentgenol 201(6):W867-76, 2013. e-Pub 2013. PMID: 24261394.

Review Articles

Leboulleux, S, Boucai, L, Busaidy, NL, Durante, C, Fagin, JA, Fazeli, S, Gianoukakis, AG, Haugen, BR, Kang, H, Konda, B, Laetsch, TW, Locati, LD, Ryder, M, Spitzweg, C, Worden, F, Wirth, L, Ho, AL. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer. The Lancet Diabetes and Endocrinology 13(6):516-527, 2025. e-Pub 2025. PMID: 40318680.
Hamidi S, Hofmann MC, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne) 14:1176731, 2023. e-Pub 2023. PMID: 37435488.
Hofmann MC, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai S, Zafereo M, Cabanillas ME. Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers. Endocr Relat Cancer 29(11):R173-R190, 2022. e-Pub 2022. PMID: 35975971.
Walgama, E, Busaidy, NL, Zafereo, M. Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer. Endocrinology and Metabolism Clinics of North America 51(2):379-389, 2022. e-Pub 2022. PMID: 35662447.
Perrier ND, Arnold A, Costa-Guda J, Busaidy NL, Nguyen H, Chuang HH, Brandi ML. New and future perspectives for parathyroid carcinoma. Endocr Relat Cancer, 2020. e-Pub 2020. PMID: 32449693.
Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Res 7, 2018. e-Pub 2018. PMID: 31583077.
Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy N. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2013. PMID: 23185034.

Professional Educational Materials

Vodopivec DM, Cabanillas ME, Busaidy NL, Gule-Monroe MK, Zafereo ME, Wang JR, Williams MD, Waguespack SG, Basset R, Maniakas A, Lai SY, Dadu R. Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer, 2022.
Busaidy NL. "Differentiated Thyroid Carcinoma", 2011.
Busaidy NL. "Thyroid Nodules: an Overview", 2011.

Editorials

Busaidy NL. Editorial on Heather Lindsey's Metformin Slows Tumor Response in Differentiated Thyroid Cancer. Oncology Times, 2014.
Busaidy NL. Association between Thyroid Hormone Suppression Therapy and Improved Outcomes. OncLive, 2014.
Busaidy NL. It Pays to Pay Attention to Glucose in Hospitalized Surgical Patients. Endocrine Today, 2010.

Abstracts

Ebrahimi S, Hamidi S, Song J, Koutroumpakis E, Ali HR, Kumar S, Mouhayar E, Dadu R, Iyer PC, Hu MI, Busaidy NL, Palaskas NL, Waguespack SG, Cabanillas ME. BRAF AND MEK INHIBITORS IN THYROID CANCER AND THE HEART: TRACKING THE INCIDENCE OF CARDIAC DYSFUNCTION AND HEART FAILURE. 75th Annual Scientific Session. e-Pub 2025.
Salim HA, Wintermark M, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Sherman SI, Waguespack SG, Grubbs EG, Wang J, Zafereo M, Hu MI. Outcomes of Brain Metastases from Medullary Thyroid Carcinoma: A Retrospective Cohort Study. American Thyroid Association, 2025. e-Pub 2025.
Hamidi S, Cabanillas M, Dadu R, Hu M, Waguespack S, Busaidy NL, Iyer P, Vickers M, Uy A, Gupta S, Adib D, Gule-Monroe M, Srour S. Safety and efficacy of second dose of AIC100 CAR T-cell in patients with poorly differentiated (PDTC) and anaplastic thyroid carcinoma (ATC). American Thyroid Association, 2025. e-Pub 2025.
Hamidi S, Waguespack S, Wang J, Weitzman S, Zafereo M, Busaidy NL, Dosiou C, Kuri D, Chen Y, Alshalalfa M, Klopper J, Hu M. The Genomic Landscape of 250,000+ Thyroid Nodules Undergoing Exome-enriched RNA Sequencing. American Thyroid Association, 2025. e-Pub 2025.
Abubaker A, Fournier I, Zafereo M, Wang JR, Banuchi V, Grubbs EG, Graham PH, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Hu MI, Iyer P, Sherman SI, Waguespack SG, Gupta SK, Ahmed S, Kwon M, Williams MD, Hosseini SM, Maniakas A. Surgical management of isthmus-confined papillary thyroid carcinoma: a single institution retrospective cohort study. American Thyroid Association. e-Pub 2025.
Greenberg L, Gonzalez-Velazquez C, Dowling E, Alexander E, Baloch Z, Brito J, Busaidy NL, Hartl D, Krane J, Langer J, Lubitx C, Newbold K, Orloff L, Pasieka J, Pattison D, Pitoia F, Robenshtok E, Rossleigh M, Roth M, Sugitani I, Tuttle M, Worden F, Zafereo M, Rauscher E, Fisher J, Urken M. Identifying Shortcomings of Global Thyroid Cancer Clinical Practice Guidelines: Introducing TIRO (Thyroid International Recommendations Online) as a Solution to Improve Guidelines Adoption Worldwide and Creation of a Standard for Dynamic Guideline Presentation. 2022 Annual Meeting of the American Thyroid Association, 2022. e-Pub 2022.
Cabanillas ME, Busaidy NL, Zafereo M, Gule-Monroe M, Liu S, Ferrarotto R, Lu C, Gross N, Fellman B, Grosu H, Williams M, Iyer P, Maniakas A, Wang J, Dadu R. BRAF/MEK Inhibitor Plus Immunotherapy for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. 2022 Annual Meeting of the American Thyroid Association, 2022. e-Pub 2022.
Shirali, A, Hu, M, Chiang YJ, Zafereo, M, Dadu R, Busaidy NL, Cabanillas M, Waguespack SG, Sherman SI, Subbian V, Graham P, Fisher S, Perrier N, Sosa J, Grubbs E. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Evaluating the Relationship Between Somatic Alteration Profile and Disease Aggressiveness. 2022 Annual Meeting of the American Thyroid Association, 2022. e-Pub 2022.
Maniakas A, Sullivan AT, Busaidy NL, Cabanillas ME, Dadu R, Fisher SB, Graham PH, Gross ND, Grubs EG, Gunn GB, Hu MI, Li X, Perrier ND, Waguespack SG, Wang JR, Williams MD, Zafereo ME. Decreasing Indications for Postoperative Adjuvant Radiation Therapy in Locoregionally-Advanced Medullary Thyroid Cancer. 90th Annual Meeting of The American Thyroid Association, 2022. e-Pub 2022.
Contrera KJ, Gule_Monroe MK, Cabanillas ME, Hu MI, Busaidy NL, Dadu R, Waguespack SG, Wang J, Myers J, Grubbs EG, Subbian V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case SEries. AHNS Annuyal Meeting at COSM 2022, 2022. e-Pub 2022.
Cabanillas ME, Dadu R, Ferrarotto R, Liu S Fellman BM, Gross ND, Gule-Monroe M, Lu C, Groso H, Williams MD, Duose DY, Mallampati S, Dervin S, Mckenna EF, Wang RJ, Zafereo M, NL|| |. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). ASCO Virtual Scientific Program, 2020. e-Pub 2020.
Fazeli S, Dadu R, Waguespack SG, Sherman SI, Busaidy NL, Hu MI, Jimenez C, Habra MA, Williams M, Altameemi L, Poropatich K, Routbort MJ, Luthra R, Patel KP, Cabanillas M. MON-491 TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center. Endocrine Society, 2020. e-Pub 2020.
Fazeli S, Dadu R, Waguespack SG, Sherman SI, Busaidy NL, Hu MI, Jimenez C, Habra MA, Williams M, Altameemi L, Poropatich K, Routbort MJ, Luthra R, Patel KP, Cabanillas M. TRK-Fusion Thyroid Cancer: A Clinical Overview in a Clinical Overview in a Large Population at a Single Cancer Center. Endocrine Society Annual Meeting 2020 All Posters, 2020. e-Pub 2020.
Maniakas A, Dadu R, Busaidy NL, Wang JR, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross N, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Revolutionizing the Therapeutic Landscape of a Deadly Disease. Thyroid 29(1), 2019. e-Pub 2019.
Graham P, Habra M, Jimenez C, Ying A, Busaidy N, Cabanillas M, Zafereo M, Perrier N, Grubbs E, Gagel R, Sherman S, Hu M. Ectopic ACTH Secretion in Medullary Thyroid Cancer: A Case Series at a Cancer Center. 89th Annual Meeting of the American Thyroid Association, Chicago, IL, 2019. e-Pub 2019.
Chaudhri A, Cabanillas M, Dadu, R, Busaidy N, Cote G, Roy S. Immunohistochemical (IHC)Testing Versus Next Generation Sequencing (NGS) for Identification of BRAF V600E Mutations in Clinical Practice for Anaplastic Thyroid Cancer. 89th Annual Meeting of the American Thyroid Association, Chicago, IL, 2019. e-Pub 2019.
Sperling J, Maniakas A, Goswami M, Cote G, Dadu R, Busaidy N, Lai S, Gross N, Goepfert RP, Sturgis E, Zafereo M, Cabanillas M, Wang JR. Prior Cancers Among Patients Newly Diagnosed with Anaplastic Thyroid Carcinoma: Prevalence and Impact on Survival. 89th Annual Meeting of the American Thyroid Association, Chicago, IL, 2019. e-Pub 2019.
Falcone R, Waguespack S, Dadu, R, Sherman S, Busaidy N, Hu M, Jimenez C, Weitzman S, Cabanillas M. Redifferentiation radioiodine (RAI)-therapy in patients (pts) with metastatic papillary, follicular and poorly differentiated thyroid cancer (TC). 89th Annual Meeting of the American Thyroid Association, Chicago, IL, 2019. e-Pub 2019.
Maxwell J, Grubbs E, Busaidy N, Cote G, Gule-Monroe M, Subbiah V, Hu M, Perrier N, Cabanillas M, Lee J, Graham P. Novel Use of a CLIA-certified CDKN2C Loss Assay in Sporadic Medullary Thyroid Carcinoma. North American Neuroendocrine Tumor Society, Boston, MA, 2019. e-Pub 2019. PMID: 31648931.
Wirth L, Wagespack S, Busaidy NL, Hu M, Grubbs E, Weitzman S, Zafereo M, Babiarz J, Yangyang H, Huang J, Kennedy GC, Walsh S, Kloos R. Genomic Landscape of FNAs Positive for Medullary Thyroid Cancer and Potential Impact on Systemic Therapy. American Society of Clinical Oncologists (ASCO), 2019. e-Pub 2019.
Cabanillas ME, NL|| |, Dadu R, Ferrarotto R, Gross N, Gule-Monroe M, Lu C, Grosu R, Williams MD, Zafereo M. Combination Vemurafenib (BRAF inhibitor)/Cobimetinib (MEK inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility. Journal of the Endocrine Society 3(1), 2019. e-Pub 2019.
Waguespack S, Busaidy NL, Hu M, Alexander EK, Grubbs E, Parangi S, Weitzman S, Wirth J, Zafereo M, Babiarz J, Hao Y, Huang J, Kennedy GC, Walsh PS, Kloos RT. Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier. Endocrine Society, 2019. e-Pub 2019.
Silva-Figueroa A, Hess K, Wu S, Dhaval P, Nilobul N, Nguyen S, McCoy K, Carty S, Fisher S, Williams M, Grubbs E, Graham P, Lee J, Shindorf M, Simonds W, Blau J, Busaidy N, Perrier. Creation and Validation of Parathyroid Cancer Prognostic Score: A Multicenter Study. AAES 40th Annual Meeting, Los Angeles, CA, 2018. e-Pub 2018.
Kutahyalioglu M, Ibrahim EY, Williams M, Dadu, R, Habra MA, Hu M, Jimenez C, Waguespack S, Ying AK, Graham PH, Busaidy N. Malignant Struma Ovarii: a Case Study. American Association of Clinical Endocrinologist 2017, 2017. e-Pub 2017.
Kutahyalioglu M, Kwatampora L, Korivi BR, Ibrahim EY, Zhou S, Cabanillas ME, Jimenez C, Dadu R, Habra MA, Fogelman D, Busaidy NL. The effects of Kinase Inhibitors on Body Composition in Endocrine Tumor Patients. ENDO 2017, The Endocrine Society 99th Annual Meeting and Expo, 2017. e-Pub 2017.
Kutahyalioglu M, Kwatampora LJ, Korivi BR, Ibrahim EI, Zhou S, Cabanillas ME, Jimenez C, Dadu R, Habra MA, Fogelman D, Busaidy NL. The Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors-Pilot Study. Endocrine Society, 2017. e-Pub 2017.
Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Ch L, Lai SY. Facilitating Anaplastic Thyroid Cancer Specialized Treatment (FAST): A model for improving access to multidisciplinary care for Anaplastic Thyroid Cancer patients. Head and Neck, 2017. e-Pub 2017. PMID: 28452157.
Kazzaz F, Jaber T, Cabanillas ME, Busaidy N, Faiz S. Significance and Management of Pleural Disease in Thyroid Malignancy. Thyroid, 2017. e-Pub 2017.
Shah MH, Wei L, Wirth LJ, Daniels GA, De Souza JA, Timmers CD, Sexton JL, Beshara M, Nichols D, Snyder N, Devine CE, Konda B, Busaidy N. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. Journal of Clinical Oncology 35, 2017. e-Pub 2017.
Cabanillas ME, Busaidy NL, Hu MI, Zafereo M, Sturgis EM, Sherman SI, Waguespack SG, Hofmann M. Neoadjuvant Vemurafenib in Patients with Locally Advanced Papillary Thyroid Cancer (PTC). European Thyroid Association 2017, 2017. e-Pub 2017.
Ibrahim EY, Kutahyalioglu M, Chasen B, Busaidy N. Artifact of 1-131 Whole-Body Scan with Hip Uptake in a Patient with Papillary Thyroid Carcinoma - a Case Report. Endocrine Society 97th Annual Meeting 2016, 2017. e-Pub 2017.
Kutahyalioglu M, Ibrahim EY, Zafereo M, Williams M, Busaidy N. Lytic sternal mass: an unusual clinical presentation of papillary thyroid microcarcinoma. Endocrine Society 97th Annual Meeting 2016, 2017. e-Pub 2017.
Cubb TD, Ibrahim EY, Sherman SI, Williams MD, Busaidy N, Weitzman S. From Thyroid Adenoma to Metastatic Carcinoma: Not All BRAF Mutations are Created Equal. Thyroid, 2017. e-Pub 2017.
Iyer P, Cote GJ, Dadu R, Ferrarotto R, Busaidy N, Hofmann M, Zafereo M, Williams MD, Subbiah V, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA Detected by Droplet Digital PCR (DDPCR) as a Biomarker in the Management of Anaplastic Thyroid Carcinoma (ATC) Patients. Thyroid, 2017. e-Pub 2017.
Danysh B, Busaidy N, Sinha D, Evans KW, Akcakanat A, Meric-Bernstam F, Cabanillas ME, Ringel MD, Shah MH, Hofmann M. BRAF Mutant Papillary Thyroid Cells with Concurrent Mutations Along the KRAS-RAC1 Axis Develop Resistance to BRAF(V600E)-Inhibitors and are Associated with Increases in EMT Markers. Thyroid, 2017. e-Pub 2017.
Konda B, Shah, MH, Wei L, Espinosa AV, Busaidy NL, Wirth LJ, Daniels GA, De Souza JA, Sexton JL, Beshara M, Liu T, Nichols D, Snyder N, Devine CE, Timmers CD. Evaluation of BRAFV600E Levels in Cell Free DNA (CFDNA) as a Biomarker of Response in BRAF V600E Mutated Radioactive Iodine Refractory (RAIR) Differentiated Thyroid Cancer (DTC) Treated with Dabrafenib Alone or in Combination with Trametinib. Thyroid, 2017. e-Pub 2017.
Iyer P, Cote GJ, Dadu R, Busaidy NL, Ferrarotto R, Hess KR, Gule-Monroe M, Subbiah V, Hofmann M, Gross ND, Zafereo M, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA (CFDNA) Detected by Droplet Digital PCR (DDPCR) as a Biomarker for Monitoring Response to Therapy in the Management of BRAF Mutated (BRAFM) Anaplastic Thyroid Carcinoma (ATC) Patients (PTS). Thyroid, 2017. e-Pub 2017.
Kwatampora L, Hamidi V, Lewis C, Williams J, Williams M, Hu M, Murphy W, Perrier N, Jimenez C, Busaidy N. Parathyroid Carcinoma Associated with Multiple Brown Tumors Mimicking Fibrous Histiocytoma - A Unique Case of Two Rare Conditions. American Association of Clinical Endocrinologists Annual Meeting 2016, 2016. e-Pub 2016.
Jaber T, Dadu R, Cabanillas M, Santos E, Shah K, Kwatampora L, El Shamsi H, Waguespack, Busaidy N. Targeted Therapy for Resensitization (or Redifferentiation) of Thyroid Cancers to Radioactive Iodine (RAI) Therapy: Perhaps a Promising Approach. 86th Annual Meeting of the American Thyroid Association, Denver, CO, 2016. e-Pub 2016.
Iyer P, Cabanillas M, Waguespack S, Busaidy N, Hu M, Dadu R. Immunotherapy-Related Destructive Thyroiditis: A Cancer Center Experience. American Thyroid Association, 2016. e-Pub 2016.
Iyer P, Dadu R, Busaidy NL, Ferrarotto R, Gule-Monroe MK, Lu C, Williams MD, Cabanillas ME. Harvesting high-hanging fruit: Targeted Therapy for BRAF mutant (BRAFm) and BRAF wild-type (BRAFwt) Anaplastic Thyroid Cancer (ATC) patients. American Thyroid Association, 2016. e-Pub 2016.
Cote G, Evers C, Hu M, Grubbs E, Hai T, Housoth M, Williams M, Duose D, Mehrotra M, Busaidy N, Waguespack S, Luthra R, Sherman S. Liquid Biopsy of cfDNA as a Predictor of Survival in Medullary Thyroid Cancer Patients with Somatic RET M918T Mutations. 86th Annual Meeting of the American Thyroid Association, Denver, CO, 2016. e-Pub 2016.
Sandulache V, Williams MD, Lai SY, Lu D, William WN, Busaidy NL, Cabanillas ME. Clinical genomic testing of anaplastic thyroid carcinoma (ATC) and need for integration into future prospective clinical trials. Journal of Clinical Oncology 34, 2016. e-Pub 2016.
Xu JY, Handy B, Waguespack S, Hu M, Busaidy N, Jimenez C, Cabanillas M, Cote G, Sherman S. Effect of Circulating Tumor Cells (CTCs) on Overall Survival in Metastatic Medullary Thyroid Cancer (metMTC). 2016 American Society of Clinical Oncology Annual Meeting, 2016. e-Pub 2016.
Thuro BA, Cabanillas ME, Busaidy NL, Dadu R, Jimenez C, Graham PH, Esmaeli B. Thyroid-related Eye Disease in Cancer Patients. International Thyroid Eye Disease Symposium Program, 2016. e-Pub 2016.
Xu JY, Zaidi T, Cote GJ, Hu MI, Waguespack SG, Cabanillas ME, Ying AK, Busaidy NL, Habra MA, Shanbhag N, Truong D, Yu RK, Shete S, Katz RL, Sherman SI. Circulating Tumor Cells (CTCs) in Metastatic Papillary Thyroid Cancer: A Report of a Case-Control Pilot Study (Poster SAT 300). The Endocrine Society's 98th Annual Meeting & Expo, Boston, Massachusetts, April 1-4, 2016, 2016. e-Pub 2016.
Silva A, Kwatampora L, Christakis I, Warneke C, Clarke C, Williams M, Grubbs E, Lee J, Perrier N, Busaidy N. Prognostic factors of overall recurrence and survival in Parathyroid Carcinoma; The largest single institution experience over the last 3 decades in USA. Endocrine Society Annual Meeting 2016, 2016. e-Pub 2016.
Xu JY, Jr MW, Milton DR, Rao SN, Jimenez C, Habra MA, Waguespack SG, Ying AK, Cabanillas ME, Grubbs EG, Weitzman SP, Busaidy NL, Gagel R, Sellin RV, Sherman SI, Hu MI. Medullary Thyroid Cancer with Bone Metastases and the Effect of Antiresorptive Agents on Skeletal Related Events: Experience at MD Anderson Cancer Center (LB-OR02-Late-Breaking Oral Session-Clinical). The Endocrine Society's 98th Annual Meeting & Expo, Boston Massachusetts, April 1-4, 2016, 2016. e-Pub 2016.
Christakis I, Busaidy N, Clarke C, Kwatampora L, Warneke C, Silva A, Williams M, Grubbs E, Lee J, Perrier N. Atypical Parathyroid Neoplasms Have a Less Accentuated Biochemical Profile and a Higher 5-year Recurrence Free Survival Compared to Parathyroid Carcinomas. Annals of Surgical Oncology, 2016. e-Pub 2016.
Rao S, Dadu R, Busaidy N, Lai S, Gunn B, Charles L, William W, Cabanillas M. Patterns of failure in anaplastic thyroid cancer (ATC) patients (pts). Endocrine Society Meeting 216, 2016. e-Pub 2016.
Cabanillas M, Gunn G, William M, Busaidy N, William W, Lu C, Lai S. Facilitating Anaplastic Specialized Treatments (FAST) - a Multidisciplinary Anaplastic Thyroid Cancer (ATC) Team. 2016 Multidisciplinary Head and Neck Cancer Symposium, 2016. e-Pub 2016.
Jaber T, Habra MA, Kwatampora LJ, Hwang LL, Perrier ND, Busaidy NL. ACTH-Dependent Ectopic Cushing's Syndrome from a Metastatic Carcinoid Neuroendocrine Tumor: How Early Is Too Early for a Bilateral Adrenalectomy?. Endocrine Society 97th Annual Meeting, 2016. e-Pub 2016.
Khan SA A, Bo C, Gerber DE, McFadden DG, Beg, MS, Xie Y, Kurian P, Cabanillas ME, Busaidy NL, Sherman SI, Heilmann A, Ross, JS, Bailey M, Burtness B, Ali SM. Comprehensive genomic sequencing (CGS) of 90 patient samples of Anaplastic Thyroid Cancer (ATC). Journal of Clinical Oncology 34, 2016. e-Pub 2016.
Kwatampora L, Clarke C, Silva A, Zorba Y, Williams M, Broaddus R, Clayman G, El-Naggar A, Gagel R, Grubbs E, Habra M, Hu M, Jimenez C, Kopetz S, Lee J, Sherman S, Vassilopoulou-Sellin R, Waguespack S, Perrier N, Busaidy N. Recurrent parathyroid carcinoma - a need to molecular profiling to aid in prognostication and therapeutics. American Society of Clinical Oncology Annual Meeting 2015, 2015. e-Pub 2015.
Kwatampora L, Williams M, Busaidy N, Carhill A. Riedel's Thyroiditis in the Spectrum of IGG4-Related Systemic Disease. American Association of Clinical Endocrinologist Annual Meeting 2015, 2015. e-Pub 2015.
Kwatampora L, Cabanillas M, Dadu R, Zhou S, Fogelman D, Rao Korivi B, Busaidy N. Effect of Cabozantinib on Body Composition in Advanced Thyroid Cancer. Endocrine Society Annual Meeting 2015, 2015. e-Pub 2015.
Jasim S, Kwatampora L, Tamboli P, Elsayes K, Busaidy N, Habra MA. Epithelioid Angiomyolipoma Mimicking Adrenocortical Carcinoma in patient with Li-Fraumeni Syndrome. Endocrine Society Annual Meeting 2015, 2015. e-Pub 2015.
Christakis I, Qiu W, Figueroa A, Cote G, Busaidy N, Lee J, Perrier N. Thymic Carcinoids in Multiple Endocrine Neoplasia Type 1 patients; Not just in male smokers, 2015. e-Pub 2015.
Christakis I, Busaidy N, Clarke C, Kwatampora L, Warneke C, Silva A, Williams M, Grubbs E, Lee J, Perrier N. Differentiating Atypical Parathyroid Neoplasm from Parathyroid Cancer, 2015. e-Pub 2015. PMID: 27160525.
Christakis I, Silva A, Busaidy N, Qiu W, Clarke C, Kwatampora L, Williams M, Graham P, Grubbs E, Lee J, Perrier N. Results of Common Preoperative Imaging Modalities of an Uncommon Disease - Parathyroid Carcinoma, 2015. e-Pub 2015.
Christakis I, Qiu W, Silva A, Busaidy N, Hyde S, Grubbs E, Yao J, Cote G, Lee J, Perrier N. Results of an 18-Year Experience with Multiple Endocrine Neoplasia Type 1 Gene Testing, 2015. e-Pub 2015.
Christakis I, Busaidy N, Cote G, Williams M, Hyde S, Figueroa A, Kwatampora L, Clarke C, Qui W, Lee J, Perrier N. Parathyroid Carcinoma and Atypical Parathyroid Neoplasm in Multiple Endocrine Neoplasia Type 1. The Journal of Clinical Endocrinology & Metabolism, 2015. e-Pub 2015.
Kopetz S, Litzenburger B, Kinya W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy N, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. Journal of Clinical Oncology 33, 2015. e-Pub 2015.
Cabanillas ME, Williams MD, Gunn B, Weitzman SP, Burke L, Busaidy NL, Ying A, William WN, Lu C, Lai S. Facilitating Anaplastic Thyroid Cancer Specialized Treatment (FAST): A model for increasing enrollment to Anaplastic Thyroid Cancer (ATC) clinical trials. 15th International Thyroid Congress, 2015. e-Pub 2015.
Kwatampora L, Dadu R, Cabanillas M, Busaidy N. The Rare Case of DTC Metastasis to the Adrenal Glands. American Thyroid Association Annual Meeting 2014, 2014. e-Pub 2014.
Dadu R, Shah K, Bassett R, Busaidy N, Waguespack S, Sherman S, Habra M, Jimenez C, Hu M, Ying A, Cabanillas M. OR52-4 Is There an Alternative Treatment Option for Patients with Advanced Papillary Thyroid Cancer (PTC) Harboring the BRAFV600E Mutation?. Thyroid Neoplasia, 2014. e-Pub 2014.
Busaidy N, Cabanillas, M Dadu R, Jimenez C, Habra M, Vaporciyan A, Morris L, Perrier N, Hoff A. Metastatic Parathyroid Carcinoma and Hypercalcemia Responds to Treatment with Sorafenib. SUN 0279-0325-Endocrine Neoplasia Case Reports, 2014. e-Pub 2014.
Kutahyalioglu M, Elsayes K, Vicens R, Sircar K, Jazaerly T, Ozsari L, Jimenez C, Waguespack S, Busaidy N, Cabanillas, M, Grubbs E, Habra M. OR27-3 Preexisting Adrenal Masses in Patients with Adrenocortical Carcinoma: Beyond Size Alone, 2014. e-Pub 2014.
Rich, TA, Cote, G, Hu M, Grubbs E, Busaidy N, Waguespack S, Gagel R, Gidley PW, Kupferman M, Jimenez C, Peterson SK, Sherman SI, Urbauer DL, Ying A. 1837736: Patients Rely on Physicians to Inform Them about New Genetic Tests for Hereditary Cancer Syndromes. Society of Surgical Oncology, 2014. e-Pub 2014.
Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. The efficacy of the natural clay, CASAD, in reducing medullary thyroid cancer (MTC)-related diarrhea and its effects on quality of life (QOL): a pilot study. 84th Annual Meeting of the American Thyroid Association, 2014. e-Pub 2014.
Dadu R, Shah C, Waguespack S, Sherman S, Habra M, Busaidy N, Jimenez C, Ying A, Hu M, Cabanillas ME. Efficacy and tolerability of vemurafenib in BRAFV600E positive papillary thyroid cancer. 83rd Annual Meeting of the American Thyroid Association, Poster, 2013. e-Pub 2013. PMID: 25353071.
Sherman SI, Michaelis C, Gornet TG, Handy BC, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Cote G. Overall Survival is Reduced in Patients with Detectable Circulating Tumor Cells from Metastatic Medullary Thyroid Cancer. 83rd Annual Meeting of the American Thyroid Association, 2013. e-Pub 2013.
Adili A, Chasen B, Dadu R, Williams M, Ali SK, Waguespack SG, Habra MA, Cote G, Busaidy N, Jimenez C, Hu MI, Sellin RV, Sherman SI, Cabanillas ME. Outcomes of Patients with Poorly Differentiated Thyroid Cancer of Follicular Origin Treated With First Line Sorafenib. 83rd Annual Meeting of the American Thyroid Association (Oral Presentation), 2013. e-Pub 2013.
Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack SG, Hu MI, Ying A, Habra MA, Jimenez C, Sellin RV, Cote G, Sherman S, Cabanillas ME. Survival and Efficacy of Salvage Tyrosine Kinase Inhibitors (TKIs) after first line Sorafenib (SOR) Failure in Patients with Advanced Differentiated Thyroid Cancer (DTC). 83rd Annual Meeting of the American Thyroid Association (Oral Presentation), 2013. e-Pub 2013.
Cabanillas ME, Holsinger FC, Sturgis EM, Habra MA, Davies MA, Munsell M, French J, Busaidy N, Hu, MI, Sherman SI. Pharmacodynamics study of neoadjuvant vemurafenib (VEM) in patients with BRAF mutated, locally advanced papillary thyroid cancer PTC); Trials in Progress Session. Journal of Clinical Oncology 31, 2013. e-Pub 2013.
Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack S, Ying A, Habra M, Thosani S, Hu M, Cabanillas M. Is 2nd line targeted therapy beneficial in patients with differentiated thyroid cancer after 1st line sorafenib failure?. 2013 American Society of Clinical Oncology Annual Meeting; Poster, 2013. e-Pub 2013.
Dadu R, Busaidy NL, Habra M, Hu M, Jimenez C, Ying A, Waguespack S, Cabanillas ME. Off label use of sorafenib in patients with differentiated thyroid cancer: Focus on tolerability profile. Texas Chapter of the American Association of Clinical Endocrinologists, 2013. e-Pub 2013.
Dadu R, Hu M, Habra M, Waguespack S, Ying A, Busaidy N, Cabanillas M. Salvage Therapy with tyrosine kinase inhibitors for differentiated thyroid carcinoma after first line sorafenib failure. 95th Annual Meeting of the Endocrine Society, 2013. e-Pub 2013.
Ying A, Jimenez C, Waguespack S, Rich T, Ayala-Ramirez M, Perrier N, Hu M, Habra M, Grubbs E, Cote G, Cabanillas M, Busaidy N, Thosani S. Characterization of Pheochromocytomas in MEN 2 with RET Condon 918 and 634 Mutations. Endocrine Society 2012 Conference, 2012. e-Pub 2012.
Patel P, Busaidy N, Jimenez C. Graves Ophthalmopathy and Pretibial Myxedema with Primary Hypothyroidism. Endocrine Society 2012 Conference, 2012. e-Pub 2012.
Busaidy, N, Williams M, Mills G, Grubbs E, Kupferman M, Habra M, Jimenez C, Hale K, Cabanillas M, Megahed N. Molecular Profiling of Advanced Thyroid Carcinomas. Endocrine Society 2012 Conference, 2012. e-Pub 2012.
Ayala-Ramirez M, Habra MA, Busaidy NL, Perrier ND, Rich TA, Waguespack SG, Phan A, Patel S, Jimenez C. Clinical Benefits of Chemotherapy in Patients with Metastatic Pheochromocytomas and Sympathetic Paragangliomas: Review of the Largest Single-Institution Experience. Endocrine Society 2011 Presidential Poster, 2011. e-Pub 2011.
Grubbs E, Busaidy N, Hale K, Williams M. Molecular Analysis of Brain Metastases from Thyroid Carcinomas. American Thyroid Association, 2011. e-Pub 2011.
Ayala-Ramirez M, Habra MA, Rich T, Cote G, Busaidy NL, Perrier N, Dickson P, Waguespack S, Phan A, Shreyaskumar P, Jimenez C. Experience with the Tyrosine Kinase Inhibitor Sunitinib in Metastasic Pheochromocytomas and Paragangliomas at The University of Texas MD Anderson Cancer Center. Endocrine Society 2011, Presidential Poster Presentation, 2011. e-Pub 2011.
Landry CS, Rich T, Jimenez C, Busaidy NL, Grubbs EG, Lee JL, Hai T, Cote G, Gagel RF, Perrier NG. Screening for Multiple Endocrine Neoplasia 1 in Young Patients with Primary Hyperparathyroidism. MEN 2010 Conference, 2010. e-Pub 2010.
Busaidy NL, De Souza JA, Zimrin A, Seiwert TY, Villaflor TY, Poluru K, Nam J, Hu M, Waguespack SW, Vokes EE, Cohen EE. Sunitinib in Progressive Metastatic Medullary Thyroid Cancer. 14th International Thyroid Congress-oral presentation, 2010. e-Pub 2010.
Varghese JM, Lu C, Kudelka A, Sherman SI, Kies MS, Busaidy NL, Cabanillas ME. Role of Cytotoxic Chemotherapy in Advanced Differentiated Thyroid Cancer: A Review of the MD Anderson (MDACC) Experience. 14th International Thyroid Congress, 2010. e-Pub 2010.
Ayala-Ramirez M, Hernandez M, Habra MA, Busaidy N, Gilbert C, Rich T, Waguespack S, Perrier N, Phan A, Patel S, Jimenez C. Role of Systemic Therapy in Metastatic Pheochromocytomas and Sympathetic Paragangliomas- Insights from a Review of the Largest Single Institutional Experience. MEN 2010 Conference, 2010. e-Pub 2010.
De Souza JA, Busaidy N, Zimrin A, Seiwert TY, Villaflor VM, Poluru KB, Reddy PL, Nam J, Vokes EE, Cohen EE. Phase II Trial of Sunitinib in Medullary Thyroid Cancer (MTC). American Society of Clinical Oncology Annual Meeting-oral presentation, 2010. e-Pub 2010.
Busaidy N, Kurzrock R, LoRusso P, Owens AD, Chen HX, Doyle L, Zhang J, Lawhorn K, Chandhasin C, Naing A. Hyperglycemia, Hypertriglyceridemia, and Hypercholesterolemia in a Phase I Trial of the Combination of an mTOR Inhibitor and IGF-1 Receptor Inhibitor. American Society of Clinical Oncology Annual Meeting, 2010. e-Pub 2010.
Ejaz S, Jamal S, Busaidy N, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical Carcinoma: The University of Texas MD Anderson Cancer Center Experience Update. American Society of Clinical Oncology Annual Meeting, 2010. e-Pub 2010.
Cabanillas ME, Kurzrock R, Sherman SI, Tsimberidou AM, Waguespack S, Naing A, Busaidy N, Gagel R, Wright JJ, Hong DS. Phase I trial of Combination Sorafenib and Tipifarnib: The Experience in Advanced Differentiated Thyroid Cancer (DTC) and Medullary Thyroid Cancer (MTC). American Society of Clinical Oncology Annual Meeting, 2010. e-Pub 2010.
Ayala-Ramirez M, Habra MA, Busaidy NL, Cote G, Rich TA, Waguespack S, Jimenez C. A Catecholamine Crisis on Mount Kilimanjaro: A Hypoxia Effect?. Endocrine Society 92nd Annual Meeting, 2010. e-Pub 2010.
Ejaz S, Waguespack SG, Sellin RV, Busaidy NL, Jimenez C, Ying AK, Hu MI, Cabanillas ME, Gagel RF, Habra MA. ACTH-Dependent Ectopic Cushing's Syndrome: The University of Texas MD Anderson Cancer Center Experience. Endocrine Society 92nd Annual Meeting, 2010. e-Pub 2010.
Ayala-Ramirez M, Hernandez M, Habra MA, Busaidy NL, Cote G, Rich TA, Waguespack S, Jimenez C. Survival Rates in Patients with Metastatic Pheochromocytomas and Paragangliomas. Endocrine Society, 2010. e-Pub 2010.
Busaidy NL, Vu T, Grubbs E, Urbauer D, Kim E, Landry C, Jimenez C, Hu MI, Waguespack SG, Gomez H, Perrier ND. 4D Neck CT Versus SPECT/CT Using Tc99m Sestamibi in the Localization of Parathyroid Adenomas: Which Study and When?. Endocrine Society 92nd Annual Meeting, 2010. e-Pub 2010.
Michaelis CL, Cote CJ, Santarpia L, Klein MJ, Gornet TG, Fritsche HA, Busaidy NL, Waguespack SG, Cabanillas ME, Hu MI, Jimenez C, Sherman SI. Detection of Circulating Tumor Cells (CTCs) in Patients with Thyroid Cancer. Endocrine Society, 2010. e-Pub 2010.
Ayala-Ramirez M, Hernandez MS, Habra MA, Busaidy NL, Cote G, Rich TA, Waguespack S, Jimenez C. Clinical Risk Factors for Malignancy in Pheochromocytomas and Paragangliomas. Endocrine Society 92nd Annual Meeting, Oral Presentation, 2010. e-Pub 2010.
Cabanillas ME, David H, Waguespack S, Sherman SI, Hernandez M, Hu M, Habra M, Busaidy N. Stable disease is an important endpointin patients with progressive, differentiated thyroid cancer treated with sorafenib. 80th Annual Meeting of the American Thyroid Association 19(S1)(S1-S93):152, 2009. e-Pub 2009.
Cabanillas ME, Waguespack SG, Bronstein Y, Williams M, Feng L, Sherman SI, Busaidy NL. Treatment (tx) with Tyrosine Kinase Inhibitors (TKIs) for Patients (pts) with Differentiated Thyroid Cancer (DTC): The MD Anderson Cancer Center (MDACC) Experience. American Society of Clinical Oncology Annual Meeting, 2009. e-Pub 2009.
Naing A, LoRusso P, Mills G, Berry D, Doyle L, Rohren E, Burger A, Chen H, Busaidy NL, Kurzrock R. Phase I study Combining an IGFR Inhibitor (IMC-A12) and an mTOR Inhibitor (Temsirolimus) in Patients with Solid Tumors or Lymphoma. American Society of Clinical Oncology Annual Meeting-Oral Presentation, 2009. e-Pub 2009.
Perrier ND, Edeiken B, Nunez R Gayed I, Jimenez C, Busaidy NL, Potylchansky E, Kee S, Vu T. A Novel Nomenclature to Classify Parathyroid Adenomas, American Association of Endocrine Surgeons, 2009. e-Pub 2009.
Shah P, Busaidy NL, Kapoor S, Sherman SI, and Lavis VR. "Steroid Hyperglycemia" Is Not Benign. American Diabetes Association, 2009. e-Pub 2009.
Feng Y, Busaidy N, Lee M, Yeung S. Differential Impact of Anti-Diabetic Treatments on Pancreatic Cancer Cell Growth in Cell Culture Conditions Mimicking Different Stages in the Natural History of Diabetes Mellitus Type 2. American Society of Clinical Oncology Annual Meeting, 2008. e-Pub 2008.
Brady V, Crawford K, Levesque C, Lavis V, Busaidy NL. Increased Insulin Requirements in Patients with Diabetes Receiving Hyper-CVAD. International MASCC/ISOO Symposium, 2008. e-Pub 2008.
Crawford K, Levesque C, Brady V, Owens A, Busaidy NL, Lavis V. Glycemic Management of Hospitalized Patients Receiving Tube Feeding in a Cancer Center. International MASCC/ISOO Symposium, 2008. e-Pub 2008.
Yazbeck CF, Gonzalez-Angulo A, Shaw SA, Waguespack SG, Vassilopoulou-Sellin R, Busaidy NL. Hypocalcemia Induced by Bisphosphonates in Cancer Patients with Vitamin D Deficiency. Endocrine Society 89th Annual Meeting, 2007. e-Pub 2007.
Kapoor S, Cui J, Busaidy N, Lavis V, Shah P. Recognized and Unrecognized Hyperglycemia in Cancer Inpatients. American Society of Clinical Oncology Annual Meeting, 2007. e-Pub 2007.
Hu MI, Busaidy NL, Sellin RV, Waguespack SG. Non-Islet Cell Tumor Hypoglycemia and Inappropriate Cortisol Response. Endocrine Society 89th Annual Meeting, 2007. e-Pub 2007.
Yazbeck CF, Clayman G, Busaidy NL. Benign Thyroid Goiter Presents with True Vocal Cord Paralysis. American Association of Clinical Endocrinology, 2007. e-Pub 2007.
Williams MD, Suliburk JW, Staerkel GA, Busaidy NL, Lee JE, Evans DB, Perrier ND. The Incidence of Occult Papillary Thyroid Carcinomas. 78th Annual Meeting of the American Thyroid Association, 2007. e-Pub 2007.
Kapoor S, Cui J, Busaidy NL, Lavis V, Shah P. Hyperglycemic Crises in Cancer Patients. American Diabetes Association, 2007. e-Pub 2007.
Prasad A, Eng C, Shah P, Lavis V, Busaidy NL. Oncologic Outcomes in Diabetic Patients with Colon Cancer. Endocrine Society 89th Annual Meeting, 2007. e-Pub 2007.
Cabanillas M, Thomas D, Waguespack S, Busaidy N, Hoff A, Mattiuzzi G, Cassat J, Brandt M, Foudray M, Escalante C, Kantarjian H, Gagel R. Vitamin D Deficiency Occurs with High Frequency in Acute Leukemia. The Bone Disease Program of Texas 4th Annual Scientific Retreat, 2006. e-Pub 2006.
Busaidy NL, Yazbeck CF, Shah P, Evans DB, Li D, Geraci JM, Weiser MA. Survival of Resectable Pancreatic Cancer Patients with Diabetes. American Society of Clinical Oncology, 2006. e-Pub 2006.
Fareau G, Busaidy NL. Papillary Thyroid Micro carcinoma with Metastatic Spread to Bone. 77th Annual Meeting of the American Thyroid Association, 2006. e-Pub 2006.
Cabanillas ME, Thomas DA, Waguespack SG, Lin E, Huang X, Palmer JL, Busaidy NL, Foudray MC, Cassat JL, Lawson A, Escalante CP, Kantarjian HM, Gagel RF. Spectrum of Hormone Abnormalities Contributing to Bone Loss in Adult Patients with Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). American Society of Bone and Mineral Research, 2006. e-Pub 2006.
Geraci JM, Busaidy NL, Wang J, Lam TP, Skibber JM, Freeman JH, Goodwin JS. Hyperglycemia Treatment is Associated with Longer Length of Hospital Stay in Colorectal, Hepatic and Pancreatic Cancer Surgery Patients. American Society of Clinical Oncology Annual Meeting, 2006. e-Pub 2006.
Cabanillas M, Thomas D, Palmer J, Mattiuzzi G, Cassat J, Foudray M, Brandt M, Lawson A, Busaidy NL, Hoff A, Kantarjian H, Gagel R. HyperCVAD Chemotherapy Causes Rapid Bone Loss in Patients with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Division of Internal Medicine Retreat, 2006. e-Pub 2006.
Cabanillas M, Sellin R, Thomas D, Bruera E, Mattiuzzi G, Busaidy N, Hoff A. Hypogonadism is Common in Adult, Male Patients Receiving Frontline Chemotherapy with Hyper-CVAD for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (ALL/LL). Division of Internal Medicine Retreat, 2006. e-Pub 2006.
Podoloff DA, Stachowiak AM, Sellin RV, Busaidy NL, Habra M, Wendt RE. Therapeutic Response to High Dose (MIBG) Metaiodobenzylguanidine Therapy for Metastatic Neuroendocrine Tumors. The Society of Nuclear Medicine, 2005. e-Pub 2005.
Geraci JM, Busaidy NL, Wang J, et al. Diabetes Mellitus is Associated with Longer Length Hospital Stay in Colorectal Cancer Surgery Patients. Division of Internal Medicine Retreat, 2005. e-Pub 2005.
Busaidy NL, Habra MA, Jimenez C, Gagel RF. Diabetes Mellitus: A Possible Paraneoplastic Syndrome?. The Endocrine Society Annual Meeting, 2004. e-Pub 2004.
Busaidy NL, Jimenez C, Habra MA, Gagel RF. Secondary or Tertiary Hyperparathyroidism in Tumor-Induced Osteomalacia. American Association of Clinical Endocrinologists, 2004. e-Pub 2004.
Habra MA, Busaidy NL, Jimenez C, Vassilopoulou-Sellin R. Cowden Syndrome Associated with Galactorrhea. American Association of Clinical Endocrinologists, 2004. e-Pub 2004.
Busaidy N, Hymes NS, Jimenez C, Habra M, Sarlis N. Progression of Medullary Thyroid Carcinoma Manifested as Skin Metastasis with Inflammatory Features. E831C1436. International Proceedings 12th International Congress of Endocrinology. Lisbon, 2004. e-Pub 2004.
Jimenez C, Habra M, Busaidy N, Dekovich A, Gagel R, Sarlis N. Portal Hypertension: Yet Another Complication of Metastatic Medullary Thyroid Carcinoma. E831C1437. International Proceedings 12th International Congress of Endocrinology. Lisbon, 2004. e-Pub 2004.
Busaidy NL, Jimenez C, et al HM. Parathyroid Carcinoma. 20 Years of Experience. Abstract #102098 at American Society of Clinical Oncology, 2003. e-Pub 2003.
Busaidy N, Jimenez C, Habra MA, Schultz PN, Klein MJ, Wirfel K, El-Naggar A, Vassilopoulou-Sellin R. Two Decades of Experience with Parathyroid Carcinoma. American Society of Clinical Oncology Annual Meeting, 2003. e-Pub 2003.
Palacios JA, Hamidi S, Abubaker A, Cabanillas ME, Dadu R, Iyer P, Busaidy N, Zafereo M, Wang R, Banuchi VE, Gunn B, Lee A, Ahmed S, Kwon M, Williams M, Mansour M, Maniakas A. Clinicopathologic Features of Papillary Thyroid Cancer (PTC)-to-Anaplastic Thyroid Carcinoma (ATC) Transformation. American Thyroid Association.
Cubb T, Iyer P, Roecker Z, Sood A, Jazaeri A, Ramalingam P, Hamidi S, Dadu R, Ying AK, Busaidy N, Waguespack S, Sherman S, Hu MI, Cabanillas M. Malignant Struma Ovarii Clinical Characteristics and Outcomes: A Retrospective Tertiary Cancer Center Experience. American Thyroid Association.
Palacios JA, Fournier I, Maniakas A, Wang RJ, Banuchi V, Lango MN, Gule-Monroe MK, Williams M, Mena M, Grubbs EG, Fisher SB, Xu L, Busaidy N, Cabanillas M, Castellanos LE, Dadu R, Hamidi S, Hu MI, Waguespack S, MZafereo. Neoadjuvant Targeted Therapy for Locally Advanced Differentiated Thyroid Carcinoma (DTC). American Thyroid Association.

Book Chapters

Wanland K, Ibrahim F, Busaidy N. Medical Treatment of Metastatic Thyroid Cancer. In: Surgical and Medical Management of Diseases of the Thyroid and Parathyroid. Plural Publishing, Incorporated, 2019.
Jaber T, Zwiener JE, Busaidy N. Local and Systemic treatment of Unresectable Disease. In: Management of Differentiated Thyroid Cancer. Springer Nature, 2017.
Kwatampora L, Weitzman S, Habra M, Vassilopoulou-Sellin R, Busaidy N. Endocrine Malignancies. In: The MD Anderson Manual of Medical Oncology 3rd Edition. 3rd, 2016.
Hu M, Jimenez C, Busaidy N, Habra M. In: Long-term and late endocrine effects of cancer survivorship. 1st. Springer, 2014.
Busaidy N, Lahoti A, A Hanley AD. Secondary Hyperparathyroidism. In: Handbook of Parathyroid Diseases. Springer, 141-158, 2012.
Habra MA, Busaidy NL, Yeung SJ, Vassilopoulou-Sellin R. Endocrine Manifestations of Nonendocrine Tumors. In: Medical Oncology. McGraw-Hill, 993-1010, 2011.
Habra MA, Busaidy NL, Yeung SJ, Vassilopoulou-Sellin R. Endocrine and Metabolic Complications of Cancer Therapy. In: Medical Oncology. Second. McGraw-Hill, 1235-55, 2011.
Busaidy NL, Kloos RT. Papillary Thyroid Carcinoma. In: Clinical Management of Thyroid Disease. Saunders, 361-382, 2009.
Pankaj S, Busaidy NL, Geraci J, Hamilton M, Weiser MA. Diabetes and the Cancer Patient. In: Medicine Care of Cancer Patients, 209-215, 2009.
Busaidy NL, Habra MA, Vassilopoulou-Sellin R. Endocrine Malignancies. In: Medical Oncology. McGraw-Hill, 819-854, 2006.
Habra MA, Busaidy NL, Yeung SJ, Vassilopoulou-Sellin R. Endocrine Manifestations of Therapy of Nonendocrine Tumors. In: Medical Oncology. McGraw-Hill, 993-1010, 2006.
Khan MI, Busaidy NL, Waguespack SG. Electrolyte Disturbances. In: Critical Care for Cancer Patients. Springer Science + Business Media, LLC.
Zweiner J, Kwatampora L, Busaidy NL. Chapter 17, Emerging Therapies for Progressive Metastatic Medullary Thyroid Cancer. In: Medullary Thyroid Cancer.
Abadin SS, Busaidy NL, Perrier ND. Targeted Therapies in Thyroid Cancer. In: Surgical Clinics of North America.

Less

CV information above last modified March 25, 2026

Naifa Lamki Busaidy, M.D., F.A.C.P., F.A.C.E.

About Dr. Naifa Lamki Busaidy

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Naifa Lamki Busaidy, M.D., F.A.C.P., F.A.C.E.

About Dr. Naifa Lamki Busaidy

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson